var title_f17_59_18352="Posterior needle bx bone tumor";
var content_f17_59_18352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67748%7EONC%2F67024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67748%7EONC%2F67024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior bone biopsy approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT-guided needle biopsy of this osteosarcoma was performed using a posterior approach. Although targeting the lytic soft tissue component for sampling was appropriate, the posterior needle track would have been difficult to excise with the specimen, and could theoretically have compromised the surgery. In this case, however, amputation was performed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior biopsy approach for a bone tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT-guided needle biopsy of this posterior soft tissue mass was accomplished using an anterior approach, which would not have compromised a planned limb-sparing procedure because the needle track could be entirely excised with the resection specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18352=[""].join("\n");
var outline_f17_59_18352=null;
var title_f17_59_18353="Open midshaft fracture";
var content_f17_59_18353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open midshaft forearm fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thirteen-year-old girl with open forearm fracture. Top Panels: AP and lateral x-rays; note extrusion of ulna on lateral view. Bottom Panels: After irrigation and debridement and flexible nail internal fixation; note the Penrose drain in the ulnar wound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18353=[""].join("\n");
var outline_f17_59_18353=null;
var title_f17_59_18354="Calculator: Fractional excretion of magnesium (SI units)";
var content_f17_59_18354=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"FractExcMg_SI_form\" name=\"FractExcMg_SI_form\" onkeydown=\"formKeyDown(event);\" onkeypress=\"return validNumberField(event);\" onkeyup=\"FractExcMg_SI_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Fractional excretion of magnesium (SI units)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          FEMg = 100 * (UrineMg * PlasmaCr) / (0.7 * PlasmaMg * UrineCr)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Mg",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Mg_param\" onblur=\"FractExcMg_SI_fx(); minMaxCheck();\" onchange=\"FractExcMg_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Mg_unit\" onchange=\"FractExcMg_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Plasma Mg",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Plasma_Mg_param\" onblur=\"FractExcMg_SI_fx(); minMaxCheck();\" onchange=\"FractExcMg_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Plasma_Mg_unit\" onchange=\"FractExcMg_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Cr",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Cr_param\" onblur=\"FractExcMg_SI_fx(); minMaxCheck();\" onchange=\"FractExcMg_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Cr_unit\" onchange=\"FractExcMg_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|micromol/L\">",
"               micromol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Plasma Cr",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Plasma_Cr_param\" onblur=\"FractExcMg_SI_fx(); minMaxCheck();\" onchange=\"FractExcMg_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Plasma_Cr_unit\" onchange=\"FractExcMg_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|micromol/L\">",
"               micromol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              FE Mg",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"FE_Mg_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"FE_Mg_unit\" onchange=\"FractExcMg_SI_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|%\">",
"                %",
"               </option>",
"               <option value=\"100|0|fraction\">",
"                fraction",
"               </option>",
"               <option value=\"100|0|ratio\">",
"                ratio",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"FractExcMg_SI_fx();\">",
"              <option selected=\"selected\">",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The fractional excretion of magnesium (",
"       <b>",
"        FEMg",
"       </b>",
"       ) can be calculated by entering the values from simultaneously obtained urine and blood samples.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Elliott C, Newman N, Madan A. Gentamicin effects on urinary electrolyte  excretion in healthy subjects.",
"        <i>",
"         Clin Pharmacol Ther",
"        </i>",
"        . 2000 Jan;67(1):16-21.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18354=[" ",
"",
"",
"var lastChar = '';",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(){",
"alert('This field is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"function validNumberField(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"var val = field.value;",
"var charCode = event.charCode;",
"var key = String.fromCharCode(charCode);",
"",
"if(charCode == 0 || charCode == 13) {",
"  return true;",
"}",
"",
"if(key == ' ') {",
"alert('Numeric field cannot contain spaces.');",
"  return false;",
"}	",
"		",
"if(key == '.') { return validDecimalPoint(val, key); }",
"if(key == '-') { return validMinus(val, key); }",
"",
"if(isNaN(parseInt(key))) {",
"alertNaN();",
"return false;",
"}",
"	",
"return validFloat(val, key);",
"}",
"return true;",
"}",
"",
"function validDecimalPoint(val, key) {",
"if(val.length == 0 && lastChar != '.') {",
"  lastChar = '.';",
"  return true;",
"}",
"if(val.indexOf('.') >= 0 || lastChar == '.') {",
" alertNaN();",
" return false;",
"}",
"if(validFloat(val, key)) {",
" lastChar = key;",
" return true;",
"}",
"lastChar = '';",
"return false;",
"}",
"",
"function validMinus(val, key) {",
"if(val.length == 0) {",
"  return true;",
"}",
"if(val.length > 1) {",
" alertNaN();",
" return false;",
"}",
"return validFloat(val, key);",
"}",
"",
"",
"function validFloat(val, key) {",
"var currentVal = parseFloat(val + key);",
"if(isNaN(val + key) || isNaN(currentVal)) {",
"alertNaN();",
"return false;",
"}",
"return true;",
"}",
"",
"function formKeyDown(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"  var val = field.value;",
"  var keyCode = event.keyCode;",
"  if(keyCode == 8 || keyCode == 127) {",
"    // backspace or delete",
"    if(lastChar == '.') {",
"      lastChar = '';",
"    }",
"    if(field.value.length == 3 && field.value[0] == '0' && field.value[1] == '.') {",
"      // this handles a backspace on an input like \".5\", which is saved internally as \"0.5\"",
"      //   otherwise, if you leave the field after the backspace, it retains \"0.5\" as the value, most likely an iOS bug",
"      field.value = ''; ",
"    }",
"  }",
"}",
"clrResults();",
"}",
"",
"function clrValue(field) {",
" field.value = '';",
" lastChar = '';",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function FractExcMg_SI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.FractExcMg_SI_form){",
"",
"",
"doCalc = true;",
"param_value = parseFloat(Urine_Mg_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Mg_unit.options[Urine_Mg_unit.selectedIndex].value.split('|');",
"Urine_Mg = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Plasma_Mg_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Plasma_Mg_unit.options[Plasma_Mg_unit.selectedIndex].value.split('|');",
"Plasma_Mg = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Urine_Cr_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Cr_unit.options[Urine_Cr_unit.selectedIndex].value.split('|');",
"Urine_Cr = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Plasma_Cr_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Plasma_Cr_unit.options[Plasma_Cr_unit.selectedIndex].value.split('|');",
"Plasma_Cr = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"FE_Mg =  100 * (Urine_Mg * Plasma_Cr) / (0.7 * Plasma_Mg * Urine_Cr);",
"",
"unit_parts = FE_Mg_unit.options[FE_Mg_unit.selectedIndex].value.split('|');",
"if (doCalc) FE_Mg_param.value = fixDP((FE_Mg - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.FractExcMg_SI_form){",
"",
"if (Urine_Mg_param.value && isNaN(Urine_Mg_param.value)){ clrValue(Urine_Mg_param); alertNaN(); }",
"if (Urine_Mg_param.value && Urine_Mg < 0) {",
"Urine_Mg = 0;",
"clrValue(Urine_Mg_param);",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Urine Mg is 0 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Urine_Mg_param.value && Urine_Mg > 103) {",
"clrValue(Urine_Mg_param);",
"clrResults();",
"Urine_Mg = 0;",
"doCalc = false;",
"alert(\"The maximum value for Urine Mg is 103 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Plasma_Mg_param.value && isNaN(Plasma_Mg_param.value)){ clrValue(Plasma_Mg_param); alertNaN(); }",
"if (Plasma_Mg_param.value && Plasma_Mg < 0) {",
"Plasma_Mg = 0;",
"clrValue(Plasma_Mg_param);",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Plasma Mg is 0 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Plasma_Mg_param.value && Plasma_Mg > 25) {",
"clrValue(Plasma_Mg_param);",
"clrResults();",
"Plasma_Mg = 0;",
"doCalc = false;",
"alert(\"The maximum value for Plasma Mg is 25 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Urine_Cr_param.value && isNaN(Urine_Cr_param.value)){ clrValue(Urine_Cr_param); alertNaN(); }",
"if (Urine_Cr_param.value && Urine_Cr < 0) {",
"Urine_Cr = 0;",
"clrValue(Urine_Cr_param);",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Urine Cr is 0 micromol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Urine_Cr_param.value && Urine_Cr > 176800) {",
"clrValue(Urine_Cr_param);",
"clrResults();",
"Urine_Cr = 0;",
"doCalc = false;",
"alert(\"The maximum value for Urine Cr is 176800 micromol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Plasma_Cr_param.value && isNaN(Plasma_Cr_param.value)){ clrValue(Plasma_Cr_param); alertNaN(); }",
"if (Plasma_Cr_param.value && Plasma_Cr < 0) {",
"Plasma_Cr = 0;",
"clrValue(Plasma_Cr_param);",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Plasma Cr is 0 micromol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Plasma_Cr_param.value && Plasma_Cr > 1768) {",
"clrValue(Plasma_Cr_param);",
"clrResults();",
"Plasma_Cr = 0;",
"doCalc = false;",
"alert(\"The maximum value for Plasma Cr is 1768 micromol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.FractExcMg_SI_form){",
"",
"FE_Mg_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f17_59_18354=null;
var title_f17_59_18355="Cold panniculitis on cheek";
var content_f17_59_18355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cold panniculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous plaque is present on the cheek of this child with cold panniculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18355=[""].join("\n");
var outline_f17_59_18355=null;
var title_f17_59_18356="EUS FNA small cell carcinoma";
var content_f17_59_18356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of small cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 68-year-old woman with a history of heavy tobacco use presented with three months of lethargy and progressive weight loss.",
"    <br/>",
"    (Panel A) Chest CT revealed left posterior periesophageal mediastinal lymphadenopathy.",
"    <br/>",
"    (Panel B) Endoscopic ultrasonography with fine needle aspiration (FNA) was requested. The needle tip can be seen entering the lymph node (LN) with the aorta adjacent to the biopsied lymph node.",
"    <br/>",
"    (Panel C) Cytology demonstrated metastatic small cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Norton ID, Wiersema MJ. Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography, Gress F, Bhattacharya I (Ed), Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18356=[""].join("\n");
var outline_f17_59_18356=null;
var title_f17_59_18357="Vismodegib: Drug information";
var content_f17_59_18357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vismodegib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/26/28068?source=see_link\">",
"    see \"Vismodegib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13765898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13797019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Erivedge&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13755425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Hedgehog Pathway Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13765936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Basal cell cancer, metastatic or locally advanced:",
"     </b>",
"     Oral: 150 mg once daily until disease progression or unacceptable toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13765938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13765937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13797020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erivedge&trade;: 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13765904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F13765903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Available at specialty pharmacies through the Erivedge Access Solutions program. Further information may be obtained from the manufacturer, Genentech, at 1-888-249-4918, or at www.ErivedgeAccessSolutions.com",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13765901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM289871.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM289871.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13765940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken with or without food. Swallow capsules whole; do not open or crush. If a dose is missed, do not make up; resume dosing with the next scheduled dose. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13753724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic basal cell carcinoma, or locally-advanced basal cell carcinoma that has recurred following surgery or in patients who are not candidates for surgery, and not candidates for radiation therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13765899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vismodegib may be confused with vandetanib, vemurafenib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13765918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (64%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Amenorrhea (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abnormal taste (55%), weight loss (45%), nausea (30%), diarrhea (29%), appetite decreased (25%), constipation (21%), vomiting (14%), loss of taste perception (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm (72%), arthralgia (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyponatremia (grade 3: 4%), hypokalemia (grade 3: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Azotemia (grade 3: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, alkaline phosphatase increased, aspiration, atrial fibrillation, back pain, corneal abrasion, dehydration, dyspnea, hyperkalemia, hypocalcemia, keratitis, lymphopenia, pneumonia, urinary tract infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13765909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13765910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Amenorrhea: Amenorrhea was observed in women of reproductive potential; it is unknown if this is reversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warnings]: May result in severe birth defects or embryo-fetal death. Teratogenic effects (severe midline defects, missing digits, and other irreversible malformations), embryotoxic, and fetotoxic events were observed in animal reproduction studies.  Verify pregnancy status prior to initiating treatment and advise patients (female and male) of the risk of birth defects, the need for contraception and risk of exposure through semen.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood donations: Advise patients not to donate blood or blood products during vismodegib treatment and for at least 7 months after the last vismodegib dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13769106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP2C19 (weak), CYP2C8 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13769104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Vismodegib. Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Vismodegib. Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Vismodegib. Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13765905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13765906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: May result in severe birth defects or embryo-fetal death. Teratogenic effects (severe midline defects, missing digits, and other irreversible malformations), embryotoxic, and fetotoxic events were observed in animal reproduction studies",
"     </b>",
"     when administered in doses less than the normal human dose. Based on its mechanism of action adverse effects on pregnancy would be expected.",
"     <b>",
"      [U.S. Boxed Warning]: Verify pregnancy status prior to initiating treatment and advise patients (female and male) of the risk of birth defects, the need for contraception and risk of exposure through semen.",
"     </b>",
"     In females of childbearing potential, obtain pregnancy test within 7 days prior to treatment initiation; after the negative pregnancy test, initiate highly effective contraception prior to the first vismodegib dose and continue during and for 7 months after treatment. Males with female partners of childbearing potential should use condoms with spermicide (even after vasectomy) during and for 2 months after treatment. Women exposed to vismodegib during pregnancy (directly or via seminal fluid) are encouraged to participate in the Erivedge Pregnancy Pharmacovigilance program by contacting the Genentech Adverse Event Line (1-888-835-2555).  Pregnancies occurring during or within 7 months after treatment should be reported to the Genentech Adverse Event Line.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13765907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13765908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13765939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Erivedge Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (28): $9450.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13765942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy test within 1 week prior to treatment initiation.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13765924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Basal cell cancer is associated with mutations in Hedgehog pathway components. Hedgehog regulates cell growth and differentiation in embryogenesis; while generally not active in adult tissue, Hedgehog mutations associated with basal cell cancer can activate the pathway resulting in unrestricted proliferation of skin basal cells. Vismodegib is a selective Hedgehog pathway inhibitor which binds to and inhibits Smoothened homologue (SMO), the transmembrane protein involved in Hedgehog signal transduction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13765926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 16.4-26.6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99%; primarily to serum albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid glycoprotein (AAG)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Metabolized by oxidation, glucuronidation, and pyridine ring cleavage, although &gt;98% of circulating components are as the parent drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: Continuous daily dosing: ~4 days; Single dose: ~12 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~2.4 days (Graham, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (82%); urine (4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Graham RA, Lum BL, Cheeti S, et al, &ldquo;Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Solid Tumors: The Role of Alpha-1-Acid Glycoprotein Binding,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2011, 17(8):2512-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18357/abstract-text/21300760/pubmed\" id=\"21300760\" target=\"_blank\">",
"        21300760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorusso PM, Jimeno A, Dy G, et al, &ldquo;Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Solid Tumors,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2011, 17(17):5774-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18357/abstract-text/21753154/pubmed\" id=\"21753154\" target=\"_blank\">",
"        21753154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LoRusso PM, Rudin CM, Reddy JC, et al, &ldquo;Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Refractory, Locally Advanced or Metastatic Solid Tumors,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2011, 17(8):2502-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18357/abstract-text/21300762/pubmed\" id=\"21300762\" target=\"_blank\">",
"        21300762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Low JA and de Sauvage FJ, &ldquo;Clinical Experience With Hedgehog Pathway Inhibitors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(36):5321-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18357/abstract-text/21041712/pubmed\" id=\"21041712\" target=\"_blank\">",
"        21041712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudin CM, Hann CL, Laterra J, et al, &ldquo;Treatment of Medulloblastoma With Hedgehog Pathway Inhibitor GDC-0449,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(12):1173-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18357/abstract-text/19726761/pubmed\" id=\"19726761\" target=\"_blank\">",
"        19726761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sekulik A, Migden M, Oro AE, et al, &ldquo;Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2012, 366(23):2171-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18357/abstract-text/22670903/pubmed\" id=\"22670903\" target=\"_blank\">",
"        22670903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al, &ldquo;Inhibiting the Hedgehog Pathway in Patients With the Basal-Cell Nevus Syndrome,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2012, 366(23):2180-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18357/abstract-text/22670904/pubmed\" id=\"22670904\" target=\"_blank\">",
"        22670904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Von Hoff DD, LoRusso PM, Rudin CM, et al, &ldquo;Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(12):1164-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18357/abstract-text/19726763/pubmed\" id=\"19726763\" target=\"_blank\">",
"        19726763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17142 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18357=[""].join("\n");
var outline_f17_59_18357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765898\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13797019\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755425\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765936\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765938\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765937\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13797020\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765904\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765903\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765901\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765940\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13753724\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765899\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765918\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765909\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765910\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769106\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769104\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765905\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765906\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765907\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765908\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765939\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322930\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765942\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765924\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765926\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17142\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17142|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/26/28068?source=related_link\">",
"      Vismodegib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_59_18358="Robot surg ports";
var content_f17_59_18358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Robotic surgical ports",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marie Fidela R Paraiso, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18358=[""].join("\n");
var outline_f17_59_18358=null;
var title_f17_59_18359="EEG tonic clonic seizure";
var content_f17_59_18359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Generalized tonic clonic epilepsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The electroencephalographic recording of the onset of a generalized tonic-clonic seizure is illustrated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18359=[""].join("\n");
var outline_f17_59_18359=null;
var title_f17_59_18360="Oseltamivir: Pediatric drug information";
var content_f17_59_18360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oseltamivir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"    see \"Oseltamivir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/16/1285?source=see_link\">",
"    see \"Oseltamivir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15845441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Expanded Pediatric Use for Oseltamivir (Tamiflu&reg;)",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) has expanded the use of oseltamivir (Tamiflu&reg;) for the treatment of influenza in children as young as 2 weeks old who have shown symptoms of influenza for &le;2 days. Previously, Tamiflu&reg; was only FDA approved for influenza treatment in children &ge;1 year of age.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Recommended dosing for influenza treatment in children &lt;1 year is 3 mg/kg twice daily for 5 days which requires that each dose be calculated using the child&rsquo;s exact weight. In addition, these smaller doses will require that the pharmacist provide a proper dosing device so that parents can accurately measure and administer the correct dose. The dosing device that is currently packaged with Tamiflu&reg; powder for oral suspension will not accurately measure the dose and should not be used for children &lt;1 year of age.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, see",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333205.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333205.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tamiflu&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tamiflu&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Neuraminidase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Influenza, treatment:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should ideally begin within 48 hours; however, initiation after 48 hours may decrease mortality or duration of illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Premature neonates:  Limited data available: GA: 24-37 weeks: Oral: 1 mg/kg/dose twice daily; duration not determined. This dose is expected to produce serum concentrations similar to treatment doses in infants and young children based on retrospective pharmacokinetic trial of 20 neonates (Acosta, 2010; Bradley, 2011; CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Full-term neonates (Bautista, 2010; Bradley, 2011; CDC, 2011; WHO, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA 0-13 days: Limited data available: Oral: 3 mg/kg/dose once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA 14-28 days: Oral: 3 mg/kg/dose twice daily for 5 days",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"      see \"Oseltamivir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Influenza, treatment:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should ideally begin within 48 hours; however, initiation after 48 hours may decrease mortality or duration of illness. Hospitalized patients may require longer (eg, &ge;10 days) treatment courses. Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Weight-based dosing (preferred):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CDC Recommendations (CDC, 2012): Manufacturer's labeling: Oral: 3 mg/kg/dose twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     IDSA/PIDS Recommendations (Bradley, 2011): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     1-8 months: 3 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     9-11 months: 3.5 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Fixed dosing (use",
"      <b>",
"       <span style=\"text-decoration: underline\">",
"        only",
"       </span>",
"      </b>",
"      if weight not available)",
"     </i>",
"     (AAP, 2010): Limited data available: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;3 months: 12 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3-5 months: 20 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-11 months: 25 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 12-23 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CDC Recommendations (CDC, 2012): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &le;15 kg: 30 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;15-23 kg: 45 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;23 kg:  See dosage recommendations below for children &ge;2 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     IDSA/PIDS Recommendations (Bradley, 2011): Oral: 3.5 mg/kg/dose twice daily; weight-dependent maximum dose: Weight &le;15 kg: 30 mg; Weight &gt;15-23 kg: 45 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;2-12 years and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer&rsquo;s labeling consistent with current CDC and IDSA/PIDS recommendations (Bradley, 2011; CDC, 2012): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;15 kg: 30 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;15-23 kg: 45 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;23-40 kg: 60 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;40 kg: 75 mg twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Influenza, prophylaxis: Note:",
"     </b>",
"     Initiate treatment within 48 hours of contact with an infected individual. Duration of prophylaxis dependent upon type of exposure or outbreak (eg, household exposure vs hospital outbreak); see below for further details.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: Limited data available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Weight-directed dosing (preferred):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CDC Recommendation (CDC, 2012): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &lt;3 months: Not recommended unless clinically critical",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     3-11 months: 3 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     IDSA/PIDS Recommendations (Bradley, 2011): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     3-8 months: 3 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     9-11 months:  3.5 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Fixed dosing (use",
"      <b>",
"       <span style=\"text-decoration: underline\">",
"        only",
"       </span>",
"      </b>",
"      if weight not available)",
"     </i>",
"     (AAP, 2010): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;3 months: Not recommended unless clinically critical",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3-5 months: 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-11 months: 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 12-23 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CDC Recommendations (CDC, 2012): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;15 kg: 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;15-23 kg: 45 mg dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;23 kg:  See dosage recommendations below for weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     IDSA/PIDS Recommendations (Bradley, 2011): Oral: 3.5 mg/kg/dose once daily; weight-dependent maximum dose: Weight: &le;15 kg:  30 mg; Weight &gt;15-23 kg:  45 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-12 years and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer&rsquo;s labeling consistent with current CDC and IDSA/PIDS recommendations (Bradley, 2011; CDC, 2012): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;15 kg: 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;15 kg to &le;23 kg: 45 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;23 kg to &le;40 kg: 60 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;40 kg: 75 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis duration:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Individual/household exposure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Manufacturer labeling: 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Alternate recommendations: 7 days (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Community/institutional outbreak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Manufacturer recommendation: May be used for up to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Alternate recommendations: Continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient (CDC, 2012) or until influenza activity in community subsides or immunity obtained from immunization (Bradley, 2011). During community outbreaks, duration of protection lasts for length of dosing period; safety and efficacy have been demonstrated for use up to 6 weeks in immunocompetent patients and safety has been demonstrated for use up to 12 weeks in patients who are immunocompromised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Influenza, prophylaxis:",
"     </b>",
"     Oral: 75 mg once daily; initiate prophylaxis within 48 hours of contact with an infected individual; duration of prophylaxis: 10 days (manufacturer recommendation) or alternatively 7 days (CDC, 2012). During community outbreaks, duration of protection lasts for length of dosing period; safety and efficacy have been demonstrated for use up to 6 weeks in immunocompetent patients and safety has been demonstrated for use up to 12 weeks in patients who are immunocompromised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis (institutional outbreak; CDC, 2012): Continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Influenza, treatment:",
"     </b>",
"     Oral: 75 mg twice daily initiated within 48 hours of onset of symptoms; duration of treatment: 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Hospitalized patients with severe influenza infection may require longer (eg, &ge;10 days) treatment courses. Some experts also recommend empirically doubling the treatment dose. Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;1 year (Schreuder, 2010): Hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;15 kg: 7.5 mg after each hemodialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;15 kg to &le;23 kg: 10 mg after each hemodialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;23 kg to &le;40 kg: 15 mg after each hemodialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 kg: 30 mg after each hemodialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment of influenza: Decrease dose to 75 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis of influenza: Decrease dose to 75 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: No recommended dosage regimens are available for patients with end-stage renal disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CAPD: 30 mg once weekly (Robson, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: 30 mg after every other session (Robson, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as phosphate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tamiflu&reg;: 30 mg, 45 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tamiflu&reg;: 6 mg/mL (60 mL) [contains sodium benzoate; tutti frutti flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer with or without food; may decrease stomach upset if administered with food; shake suspension well before use. Capsules may be opened and mixed with sweetened liquid (eg, chocolate syrup, caramel topping). May be administered via naso- or orogastric tube in mechanically-ventilated patients; for a 150 mg dose (in adults), dissolve powder from two 75 mg capsules in 20 mL of sterile water and inject down the NG/OG tube; follow with a 10 mL sterile water flush (Taylor, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reconstitution, powder for suspension: Verify product formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      New concentration (6 mg/mL):",
"     </b>",
"     Reconstitute with 55 mL of water to a final concentration of 6 mg/mL (to make 60 mL total suspension)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: Store powder for suspension at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Once reconstituted, store suspension under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Use within 10 days of preparation if stored at room temperature or within 17 days of preparation if stored under refrigeration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of influenza infection in patients who have been symptomatic for no more than 2 days (FDA approved in ages &ge;2 weeks and adults); prophylaxis of influenza exposures (FDA approved in ages &ge;1 year and adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Has also been used for treatment or prophylaxis of influenza in ages &lt;1 year and treatment of patients symptomatic for &gt;2 days with severe illness (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends that antiviral",
"     <b>",
"      treatment",
"     </b>",
"     be considered for the following (see specific antiviral product monograph for appropriate patient selection):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons with severe, complicated or progressive illness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hospitalized persons",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons at higher risk for influenza complications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Children &lt;2 years of age (highest risk in children &lt;6 months of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Adults &ge;65 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     -	Persons with chronic disorders of the pulmonary (including asthma) or cardiovascular systems (except hypertension)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Persons with chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders (including sickle cell disease), or immunosuppression (including immunosuppression caused by medications or HIV)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Persons with neurologic/neuromuscular conditions (including conditions such as spinal cord injuries, seizure disorders, cerebral palsy, stroke, mental retardation, moderate to severe developmental delay, or muscular dystrophy) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Pregnant or postpartum women (&le;2 weeks after delivery)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Persons &lt;19 years of age on long-term aspirin therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - American Indians and Alaskan Natives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Persons who are morbidly obese (BMI &ge;40)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Residents of nursing homes or other chronic care facilities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Use may also be considered for previously healthy, non-high-risk outpatients with confirmed or suspected influenza based on clinical judgment when treatment can be started within 48 hours of illness onset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The ACIP recommends that",
"     <b>",
"      prophylaxis",
"     </b>",
"     be considered for the following (",
"     <b>",
"      Note",
"     </b>",
"     : Postexposure chemoprophylaxis is generally only recommended when it can be started within 48 hours of most recent exposure) (see specific antiviral product monograph for appropriate patient selection):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Postexposure prophylaxis may be considered for family or close contacts of suspected or confirmed cases, who are at higher risk of influenza complications, and who have not been vaccinated against the circulating strain at the time of the exposure or if exposure occurred within 2 weeks of vaccination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Postexposure prophylaxis may be considered for unvaccinated healthcare workers who had occupational exposure without protective equipment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pre-exposure prophylaxis should only be used for persons at very high risk of influenza complications and who cannot be otherwise protected at times of high risk for exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Prophylaxis should also be administered to all eligible residents of institutions that house patients at high risk when needed to control outbreaks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The ACIP recommends that treatment and prophylaxis be given to children &lt;1 year of age when indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamiflu&reg; oral suspension: 75 mg dose delivers 2 g sorbitol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hospitalized patients with severe 2009 H1N1 influenza infection may require longer (eg, &ge;10 days) treatment courses. Some experts also recommend empirically doubling the treatment dose. Doubling the dose in adult outpatients was not associated with increased adverse events. As no double dose studies have been published in children, use caution. Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza [interim recommendations (CDC, 2010)].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The absence of symptoms does not rule out viral influenza infection and clinical judgment should guide the decision for therapy. Treatment should not be delayed while waiting for the results of diagnostic tests. Treatment should be considered for high-risk patients with symptoms despite a negative rapid influenza test when the illness cannot be contributed to another cause. Use of oseltamivir is not a substitute for vaccination (when available); susceptibility to influenza infection returns once therapy is discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tamiflu&reg; may be confused with Tambocor&trade;, Thera-Flu&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oseltamivir (Tamiflu&reg;) oral suspension is available in a 6 mg/mL concentration and is packaged with an oral syringe calibrated in",
"       <b>",
"        milliliters",
"       </b>",
"       up to a total of 10 mL.",
"       <b>",
"        Instructions to the patient should be provided based on these units of measure (ie, mL). When providing oseltamivir suspension for children &lt;1 year of age, use a lower calibrated (ie, &lt;10 mL) oral syringe to ensure accurate dosing.",
"       </b>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       When commercially-prepared oseltamivir oral suspension is not available, an extemporaneously prepared suspension may be compounded to provide a 6 mg/mL concentration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F204143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Allergy, anaphylactic/anaphylactoid reaction, angina, arrhythmia, confusion, erythema multiforme, fracture, gastrointestinal bleeding, hemorrhagic colitis, hepatitis, liver function tests abnormal, neuropsychiatric events, pseudomembranous colitis, pyrexia, seizure, Stevens-Johnson syndrome, swelling of face or tongue, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oseltamivir, any component, or other sialic acid-based neuraminidase inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with renal impairment. Use suspension with caution in patients with hereditary fructose intolerance since 75 mg oral suspension delivers 2 g sorbitol which is greater than the maximum daily limit; may cause diarrhea and dyspepsia. Oseltamivir is not a substitute for the influenza virus vaccine. As an antiviral agent, it will not prevent primary or concomitant bacterial infections that may occur with influenza virus. Antiviral treatment should begin within 48 hours of symptom onset; however, the CDC recommends that treatment may still be beneficial and should be started in hospitalized patients with severe, complicated or progressive illness if &gt;48 hours. Treatment should not be delayed while awaiting results of laboratory tests for influenza. Nonhospitalized persons who are not at high risk for developing severe or complicated illness and who have a mild disease are not likely to benefit if treatment is started &gt;48 hours after symptom onset. Nonhospitalized persons who are already beginning to recover do not need treatment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There have been postmarketing reports of neuropsychiatric events in children (including self-injury with fatalities, hallucination, confusion, and delirium). Closely monitor patients for signs of any unusual behavior. Rare but severe hypersensitivity reactions (anaphylaxis, severe dermatologic reactions) have been associated with use. Oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; use oral suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase serum concentrations of the active metabolite(s) of Oseltamivir. Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary.  Increase monitoring for adverse events, such as thrombocytopenia.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1049065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food has no significant effect on peak oseltamivir plasma concentration or AUC",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal reproduction studies, a dose-dependent increase in the rates of minor skeleton abnormalities was found in exposed offspring. The rate of each abnormality remained within the background rate of occurrence in the species studied. Oseltamivir phosphate and its active metabolite oseltamivir carboxylate cross the placenta (",
"     <i>",
"      in vitro",
"     </i>",
"     data). An increased risk of adverse neonatal outcomes has generally not been observed following maternal use of oseltamivir during pregnancy. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Oseltamivir and zanamivir are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks postpartum. Oseltamivir and zanamivir are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (consult current CDC guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, serum glucose in patients with diabetes mellitus; signs or symptoms of unusual behavior, including attempts at self-injury, confusion, and/or delirium",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Critically ill patients: Repeat rRT-PCR or viral culture may help to determine ongoing viral replication",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits influenza virus neuraminidase which is responsible for detachment of virions from the infected cell's membrane and for viral penetration through respiratory secretions resulting in the inability of the virus to spread within the respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1049061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction in the median time to improvement: 1.3 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 23-26 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 3% (oseltamivir carboxylate); 42% (oseltamivir phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug oseltamivir phosphate is metabolized by hepatic esterases to oseltamivir carboxylate (active); neither oseltamivir phosphate or oseltamivir carboxylate are a substrate, inducer, or inhibitor of cytochrome P450 isoenzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oseltamivir phosphate: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oseltamivir carboxylate: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &gt;99% of oseltamivir carboxylate is eliminated by renal excretion via glomerular filtration and tubular secretion",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/16/1285?source=see_link\">",
"      see \"Oseltamivir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oseltamivir is not a substitute for the annual flu vaccination. Must be taken within 2 days of contact with an infected individual or onset of flu symptoms (eg, fever, cough, headache, fatigue, muscular weakness, and sore throat).  May cause dizziness, nausea, vomiting, loose stools, headache, or feeling tired and weak. Report hallucinations, unusual behavior, or inability to think clearly.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F5383847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     If the commercially prepared oral suspension is not available, the manufacturer provides the following compounding information to prepare a",
"     <b>",
"      6 mg/mL",
"     </b>",
"     suspension in emergency situations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     1. Place the specified amount of water into a polyethyleneterephthalate (PET) or glass bottle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     2. Carefully separate the capsule body and cap and pour the contents of the required number of 75 mg capsules into the PET or glass bottle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     3. Gently swirl the suspension to ensure adequate wetting of the powder for at least 2 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     4. Slowly add the specified amount of vehicle to the bottle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     5. Close the bottle using a child-resistant cap and shake well for 30 seconds to completely dissolve the active drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     6. Label &ldquo;Shake Well Before Use.&rdquo;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Stable for 35 days refrigerated or 5 days at room temperature. Shake gently prior to use. Do",
"     <b>",
"      not",
"     </b>",
"     dispense with dosing device provided with commercially-available product.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Preparation of Oseltamivir 6 mg/mL Suspension",
"     </caption>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Body Weight",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Total Volume per Patient",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         # of 75 mg Capsules",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Required Volume of Water",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Required Volume of Vehicle",
"         <sup>",
"          2,3",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Treatment Dose (wt based)",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Prophylactic Dose (wt based)",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Entire course of therapy.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Based on total volume per patient.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Acceptable vehicles are cherry syrup, Ora-Sweet&reg; SF, or simple syrup.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Using 6 mg/mL suspension.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;15 kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         69 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mL (30  mg) twice daily for 5 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mL (30  mg) once daily for 10 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16-23 kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         91 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5 mL (45 mg) twice daily for 5 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5 mL (45 mg) once daily for 10 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24-40 kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mL (60 mg) twice daily for 5 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mL (60 mg) once daily for 10 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;41 kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         137 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.5 mL (75 mg) twice daily for 5 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.5 mL (75 mg) once daily for 10 days",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Acosta EP, Jester P, Gal P, et al, \"Oseltamivir Dosing for Influenza Infection in Premature Neonates,\"",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 2010, 202(4):563-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/20594104/pubmed\" id=\"20594104\" target=\"_blank\">",
"        20594104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Antiviral Agents For the Treatment and Prophylaxis of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60 (RR-1): 1-25.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Influenza Antiviral Medications: Summary for Clinicians.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm\" target=\"_blank\">",
"       file://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm",
"      </a>",
"      . Accessed on November 26, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Intensive-Care Patients with Severe Novel Influenza A (H1N1) Virus Infection,&rdquo; July, 17, 2009. Available at: file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5827a4.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Center for Disease Control and Prevention, \"Interim Guidance on the Use of Influenza Antiviral Agents During the 2010-2011 Influenza Season, December 15, 2010.\" Available at",
"      <a href=\"file://www.cdc.gov/flu/professionals/antivirals/index.htm\" target=\"_blank\">",
"       file://www.cdc.gov/flu/professionals/antivirals/index.htm",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harper SA, Bradley JS, Englund JA, et al, \"Seasonal Influenza in Adults and Children - Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(8):1003-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/19281331/pubmed\" id=\"19281331\" target=\"_blank\">",
"        19281331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hayden FG, Atmar RL, Schilling M, et al, &ldquo;Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(18):1336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/10536125/pubmed\" id=\"10536125\" target=\"_blank\">",
"        10536125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kimberlin DW, Shalabi M, Abzug MJ, et al, \"Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, Nov 25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/19949363/pubmed\" id=\"19949363\" target=\"_blank\">",
"        19949363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robson R, Buttimore A, Lynn K, et al, \"The Pharmacokinetics and Tolerability of Oseltamivir Suspension in Patients on Haemodialysis and Continuous Ambulatory Peritoneal Dialysis,\"",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2006, 21(9):2556-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/16799169/pubmed\" id=\"16799169\" target=\"_blank\">",
"        16799169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schreuder MF, van der Flier M, Knops NB, et al, \"Oseltamivir Dosing in Children Undergoing Hemodialysis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(10):1427-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/20397934/pubmed\" id=\"20397934\" target=\"_blank\">",
"        20397934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor WRJ, Thinh BN, Anh GT, et al, &ldquo;Oseltamivir is Adequately Absorbed Following Nasogastric Administration to Adult Patients With Severe H5N1 Influenza,&rdquo;",
"      <i>",
"       PLoS One",
"      </i>",
"      , 2008, 3(10):e3410.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/18923671/pubmed\" id=\"18923671\" target=\"_blank\">",
"        18923671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treanor JJ, Hayden FG, Vrooman PS, et al, &ldquo;Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial. US Oral Neuraminidase Study Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 283(8):1016-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/ 10697061 /pubmed\" id=\" 10697061 \" target=\"_blank\">",
"        10697061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whitley RJ, Hayden FG, Reisinger KS, et al, \"Oral Oseltamivir Treatment of Influenza in Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2001, 20(2):127-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/11224828/pubmed\" id=\"11224828\" target=\"_blank\">",
"        11224828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, et al, \"Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(18):1708-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18360/abstract-text/20445182/pubmed\" id=\"20445182\" target=\"_blank\">",
"        20445182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) 2009 and Other Influenza Viruses.&rdquo; Available at: file://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12662 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18360=[""].join("\n");
var outline_f17_59_18360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15845441\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204115\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204116\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049056\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444085\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049049\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204091\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204077\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049059\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049052\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049058\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204146\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204143\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049063\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049048\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049047\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299796\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204086\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049065\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204088\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204099\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049055\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049046\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049061\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049062\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049054\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5383847\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12662\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12662|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=related_link\">",
"      Oseltamivir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/16/1285?source=related_link\">",
"      Oseltamivir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_59_18361="Paroxetine: Pediatric drug information";
var content_f17_59_18361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paroxetine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"    see \"Paroxetine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/12/17606?source=see_link\">",
"    see \"Paroxetine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Paxil CR&reg;;",
"     </li>",
"     <li>",
"      Paxil&reg;;",
"     </li>",
"     <li>",
"      Pexeva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Paroxetine&reg;;",
"     </li>",
"     <li>",
"      CO Paroxetine;",
"     </li>",
"     <li>",
"      Dom-Paroxetine;",
"     </li>",
"     <li>",
"      Mylan-Paroxetine;",
"     </li>",
"     <li>",
"      Novo-Paroxetine;",
"     </li>",
"     <li>",
"      Paxil CR&reg;;",
"     </li>",
"     <li>",
"      Paxil&reg;;",
"     </li>",
"     <li>",
"      PHL-Paroxetine;",
"     </li>",
"     <li>",
"      PMS-Paroxetine;",
"     </li>",
"     <li>",
"      ratio-Paroxetine;",
"     </li>",
"     <li>",
"      Riva-Paroxetine;",
"     </li>",
"     <li>",
"      Sandoz-Paroxetine;",
"     </li>",
"     <li>",
"      Teva-Paroxetine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"      see \"Paroxetine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     For maintenance therapy, use lowest effective dose and periodically reassess need for continued treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved. Limited information is available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     <b>",
"      The FDA recommends that paroxetine",
"     </b>",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       not",
"      </span>",
"     </b>",
"     <b>",
"      be used in pediatric patients for the treatment of depression.",
"     </b>",
"     Three well-controlled trials in pediatric patients with depression have failed to show therapeutic superiority over placebo; in addition, an increased risk for suicidal behavior was observed in patients receiving paroxetine when compared to other SSRIs (Dopheide, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Obsessive-compulsive disorder (OCD)",
"     </b>",
"     : A 12-week open-label trial of paroxetine in 20 outpatients 8-17 years of age demonstrated the potential clinical usefulness in pediatric OCD; doses were initiated at 10 mg/day and could be increased every 2 weeks by no more than 10 mg/day increments, to a maximum of 60 mg/day (Rosenberg, 1999). Efficacy of paroxetine was demonstrated in a 10-week, randomized, double-blind, placebo-controlled trial conducted in 207 pediatric patients (aged 7-17 years) with OCD; paroxetine doses were initiated at 10 mg/day and could be increased no more often than every 7 days by 10 mg/day increments, to a maximum dose of 50 mg/day; the overall mean dose was 20.3 mg/day for children and 26.8 mg/day for adolescents (Geller, 2004). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Self-injurious behavior:",
"     </b>",
"     A 15-year old autistic male with self-injurious behavior was successfully treated with paroxetine 20 mg/day (Snead, 1994). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Social phobia:",
"     </b>",
"     A small case series reported the effective use of paroxetine in 5 pediatric patients with social phobia [2 children (7 and 11 years of age) and 3 adolescents (16, 17, and 18 years of age)]; comorbid diagnoses (obsessive compulsive disorder and/or dysthymia) existed in 3 patients; doses were adjusted on an individual basis; the 7-year old was started on 2.5 mg/day and increased to 5 mg/day after 4 weeks; the 11-year old was started on 5 mg/day and the dose was titrated upwards by 5 mg/day increments every 3-4 weeks to 15 mg/day; adolescents were started on &le;20 mg/day (Mancini, 1999). A 16-week multicenter, randomized, double-blind, placebo-controlled trial reported the efficacy of paroxetine in pediatric patients (aged 8-17 years) with social anxiety disorder; 163 patients were randomized to receive paroxetine; doses were initiated at 10 mg/day and could be increased every 7 days by 10 mg/day increments, to a maximum dose of 50 mg/day; the overall mean dose was 21.7 mg/day for children and 26.1 mg/day for adolescents (Wagner, 2004). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Paxil&reg;, Pexeva&reg;: Initial: 20 mg/day given once daily preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Paxil CR&reg;: Initial: 25 mg/day given once daily preferably in the morning; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 62.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Generalized anxiety disorder:",
"     </b>",
"     Paxil&reg;, Pexeva&reg;: Initial: 20 mg/day given once daily preferably in the morning; recommended dose: 20 mg/day; range: 20-50 mg/day; doses &gt;20 mg may not have additional benefit; if dose is increased, adjust in increments of 10 mg/day at intervals of at least 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Obsessive compulsive disorder:",
"     </b>",
"     Paxil&reg;, Pexeva&reg;: Initial: 20 mg/day given once daily preferably in the morning; increase by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 20-60 mg/day; maximum dose: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Panic disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Paxil&reg;, Pexeva&reg;: Initial: 10 mg/day given once daily preferably in the morning; increase by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 10-60 mg/day; maximum dose: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Paxil CR&reg;: Initial: 12.5 mg/day given once daily preferably in the morning; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Post-traumatic stress disorder:",
"     </b>",
"     Paxil&reg;: Initial: 20 mg/day given once daily preferably in the morning; recommended dose: 20 mg/day; range: 20-50 mg/day; doses of 40 mg/day have not been shown to be of greater benefit than 20 mg/day; if indicated, increase dose by 10 mg/day increments at intervals of at least 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Premenstrual dysphoric disorder:",
"     </b>",
"     Paxil CR&reg;: Initial: 12.5 mg/day given once daily preferably in the morning; increase if needed to 25 mg/day after at least 1 week; may be given daily throughout the menstrual cycle",
"     <b>",
"      or",
"     </b>",
"     limited to the luteal phase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Social anxiety disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Paxil&reg;: Initial: 20 mg/day given once daily preferably in the morning; recommended dose: 20 mg/day; range: 20-60 mg/day; doses &gt;20 mg may not have additional benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Paxil CR&reg;: Initial: 12.5 mg/day given once daily preferably in the morning; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 37.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in severe hepatic or renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Paxil&reg;, Pexeva&reg;: Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Paxil CR&reg;: Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as hydrochloride [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;: 10 mg/5 mL (250 mL) [contains propylene glycol; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride [strength expressed as base]: 10 mg, 20 mg, 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;: 10 mg, 20 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;: 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mesylate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pexeva&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pexeva&reg;: 20 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pexeva&reg;: 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, enteric coated, oral, as hydrochloride [strength expressed as base]: 12.5 mg, 25 mg, 37.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil CR&reg;: 12.5 mg, 25 mg, 37.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, enteric coated, oral, as hydrochloride [strength expressed as base]: 12.5 mg, 25 mg, 37.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes suspension, tablet (mesylate)",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Paxil CR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088676.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088676.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pexeva&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088684.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088684.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May be administered without regard to meals; administration with food may decrease GI side effects; shake suspension well before use. Do not chew or crush immediate or controlled release tablet, swallow whole",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release tablet: Hydrochloride: Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F);  mesylate: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from humidity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral suspension and controlled release tablet: Store &le;25&deg;C (77&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paxil&reg;: Treatment of major depressive disorder (MDD), panic disorder (with or without agoraphobia), obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) (All indications: FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paxil CR&reg;: Treatment of major depressive disorder (MDD), panic disorder (with or without agoraphobia), social anxiety disorder (social phobia), and premenstrual dysphoric disorder (PMDD) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pexeva&reg;: Treatment of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder (with or without agoraphobia), and generalized anxiety disorder (GAD) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F206646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PARoxetine may be confused with FLUoxetine, PACLitaxel, piroxicam, pyridoxine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Paxil&reg; may be confused with Doxil&reg;, PACLitaxel, Plavix&reg;, PROzac&reg;, Taxol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F206643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension, palpitation, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, agitation, amnesia, anxiety, chills, concentration impaired, confusion, depersonalization, dizziness, emotional lability, headache, insomnia, nervousness, somnolence, vertigo, yawning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, libido decreased, orgasmic disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased/increased, constipation, diarrhea, dyspepsia, flatulence, nausea, taste perversion, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculatory disturbances, genital disorder, impotence, urinary frequency, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, myasthenia, myoclonus, myopathy, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis, respiratory disorder, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, adrenergic syndrome, akinesia, alkaline phosphatase increased, allergic reaction, anaphylaxis, anemias (various), angina pectoris, angioedema, aphasia, aphthous stomatitis, arrhythmias (atrial and ventricular), arthrosis, asthma, bilirubinemia, bleeding time increased, blood dyscrasias, bloody diarrhea, bradycardia, bronchitis, bulimia, BUN increased, bundle branch block, cardiospasm, cataract, cellulitis, cerebral ischemia, cerebrovascular accident, cholelithiasis, colitis, congestive heart failure, creatine phosphokinase increased, deafness, delirium, diabetes mellitus, drug dependence, dyskinesia, dysphagia, eclampsia, emphysema, erythema, exfoliative dermatitis, extrapyramidal syndrome, fecal impactions, fungal dermatitis, gamma globulins increased, gastroenteritis, glaucoma, goiter, Guillain-Barr&eacute; syndrome, hallucinations, hematemesis, hematoma, hemorrhage, hemoptysis, hepatic necrosis, hepatitis, hypercholesteremia, hyper-/hypoglycemia, hyper-/hypothyroidism, hypotension, ileus, intestinal obstruction, ketosis, lactic dehydrogenase increased, liver function tests abnormal, low cardiac output, lung fibrosis, lymphadenopathy, meningitis, MI, migraine, myelitis, myocardial ischemia, neuroleptic malignant syndrome, neuropathy, osteoporosis, pancreatitis, pancytopenia, peptic ulcer, peritonitis, phlebitis, pneumonia, platelet count abnormalities, pulmonary edema, pulmonary embolus, pulmonary hypertension, seizure, sepsis, serotonin syndrome, sperm activity altered, sperm DNA fragmentation (abnormal) increased, status epilepticus, Stevens-Johnson syndrome, suicidal tendencies, syncope, tetany, thrombophlebitis, thrombosis, torsade de pointes, toxic epidermal necrolysis, vasculitic syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to paroxetine or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur); concurrent use of thioridazine or pimozide",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of seizures, mania, renal disease, cardiac disease, or hepatic disease and in suicidal patients, children, or during breast-feeding in lactating women. Modify dosage in patients with renal or hepatic impairment. May cause hyponatremia, use with caution in patients with volume depletion or diuretic use. May cause abnormal bleeding (eg, ecchymosis, purpura, upper GI bleeding); use with caution in patients with impaired platelet aggregation and with concurrent use of aspirin, NSAIDs, or other drugs that affect coagulation. May cause akathisia (psychomotor restlessness), usually within the first few weeks of initiation of therapy. SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents and is more prevalent in adolescents compared to adults (Safer, 2006). No clinical studies have assessed the combined use of paroxetine and electroconvulsive therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. All patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy. SSRI-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents (Safer, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Avoid abrupt discontinuation; discontinuation symptoms (including agitation, dysphoria, anxiety, confusion, dizziness, hypomania, nightmares, and other symptoms) may occur if therapy is abruptly discontinued or dose reduced; taper dosage gradually in patients receiving &gt;20 mg/day to minimize risks of discontinuation symptoms; if intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). Potentially fatal serotonin syndrome may occur when SSRIs are used in combination with serotonergic drugs (eg, triptans) or drugs that impair the metabolism of serotonin (eg, MAO inhibitors).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     An increased risk of birth defects (specifically cardiovascular malformations) has been reported when paroxetine was taken during the first trimester of pregnancy. The majority of heart defects were ventricular and atrial septal defects (VSD and ASD), some of which required surgical correction. Use paroxetine during pregnancy only if the potential benefits to the mother outweigh the possible risks to the fetus. Administration of paroxetine during late third trimester may result in adverse effects or paroxetine withdrawal syndrome in the newborn (consider risks and benefits; use with caution during late third trimester). Exposure to SSRIs late in pregnancy may also be associated with an increased risk for persistent pulmonary hypertension of the newborn (Chambers, 2006). Postmarketing reports of premature births in pregnant women receiving paroxetine or other SSRIs have been noted.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F206630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (moderate), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (strong), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of PARoxetine. PARoxetine may decrease the serum concentration of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: PARoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose adjustment is recommended, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asenapine: May increase the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of DULoxetine. Management: Coadminister with caution.  If duloxetine and paroxetine are used in combination, monitor for signs and symptoms of serotonin toxicity/serotonin syndrome, as well as other toxic effects of duloxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of PARoxetine. The active metabolite amprenavir is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: PARoxetine may decrease serum concentrations of the active metabolite(s) of Fosaprepitant. Fosaprepitant may decrease the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: May enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: PARoxetine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tryptophan supplements may increase serious side effects; its use is",
"     <b>",
"      not recommended.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release: Food or milk does not significantly affect extent of absorption; food may slightly increase AUC (by 6%), increase peak concentration by 29%, and decrease time to peak from 6.4 hours to 4.9 hours postdose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Controlled release: Bioavailability is not affected by food",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in pregnant women have demonstrated a risk to the fetus. Paroxetine crosses the placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of paroxetine or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of paroxetine may be altered. The maternal CYP2D6 genotype also influences paroxetine plasma concentrations during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The manufacturer suggests discontinuing paroxetine or switching to another antidepressant unless the benefits of therapy justify continuing treatment during pregnancy; consider other treatment options for women who are planning to become pregnant. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. The ACOG also recommends that therapy with paroxetine be avoided during pregnancy if possible and that fetuses exposed in early pregnancy be assessed with a fetal echocardiography. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. The use of paroxetine is not recommended as first line therapy during pregnancy. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, liver and renal function. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paroxetine is a selective serotonin reuptake inhibitor (SSRI), chemically unrelated to tricyclic, tetracyclic, or other antidepressants; the inhibition of serotonin reuptake from CNS neuronal synapses potentiates serotonin activity in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antidepressant effects: Within 1-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antiobsessional and antipanic effects: Up to several weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     (adults): Mean: 8.7 L/kg; range: 3-28 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive by cytochrome P450 enzymes via oxidation and methylation followed by glucuronide and sulfate conjugation; nonlinear kinetics may be seen with higher doses and longer duration of therapy due to saturation of P450 2D6 (CYP2D6), an enzyme partially responsible for metabolism.",
"     <b>",
"      Note:",
"     </b>",
"     Paroxetine pharmacokinetics have not been studied in patients deficient in CYP2D6 (ie, poor metabolizers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release tablet and oral suspension have equal bioavailability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: Mean: 21 hours; range: 3-65 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     As hydrochloride: Mean: 5.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     As mesylate: Mean: 8.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Metabolites are excreted in urine and bile; 2% of drug excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/12/17606?source=see_link\">",
"      see \"Paroxetine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of paroxetine. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol, tryptophan supplements, and the herbal medicine St John's wort; avoid aspirin, NSAIDs, or other drugs that affect coagulation (may increase risks of bleeding); may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause photosensitivity reactions; avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); use a sunscreen; contact physician if reaction occurs; may cause dry mouth. Some medicines should not be taken with paroxetine or should not be taken for a while after paroxetine has been discontinued; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. Take as directed; do not alter dose or frequency without consulting prescriber; avoid abrupt discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paroxetine is more potent and more selective than other SSRIs (eg, fluoxetine, fluvoxamine, sertraline, and clomipramine) in the inhibition of serotonin reuptake. If used for an extended period of time, long-term usefulness of paroxetine should be periodically re-evaluated for an individual patient. Paxil CR&reg; tablets contain a degradable polymeric matrix (that controls the dissolution rate over &sim;4-5 hours) and an entering coating (that delays drug release until tablets leave the stomach). A recent report describes 5 children (age: 8-15 years) who developed epistaxis (n=4) or bruising (n=1) while receiving SSRI therapy (sertraline) (Lake, 2000). Another recent report describes the SSRI discontinuation syndrome in 6 children; the syndrome was similar to that reported in adults (Diler, 2002).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Neonates born to women receiving SSRIs late during the third trimester may experience respiratory distress, apnea, cyanosis, temperature instability, vomiting, feeding difficulty, hypoglycemia, constant crying, irritability, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, and seizures; these symptoms may be due to a direct toxic effect, withdrawal syndrome, or (in some cases) serotonin syndrome. Withdrawal symptoms occur in 30% of neonates exposed to SSRIs",
"     <i>",
"      in utero",
"     </i>",
"     ; monitor newborns for at least 48 hours after birth; long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to SSRIs are unknown (Levinson-Castiel, 2006).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18361/abstract-text/16467545 /pubmed\" id=\"16467545 \" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diler RS and Avci A, &ldquo;Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome in Children: Six Case Reports,&rdquo;",
"      <i>",
"       Current Therapeutic Reseach",
"      </i>",
"      , 2002, 63(3):188-97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, Reed MD, and Blumer JL, &ldquo;Pharmacological Treatment of Depression in Children and Adolescents,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 1999, 1(3):161-82.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller DA, Wagner KD, Emslie G, et al, \"Paroxetine Treatment in Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2004, 43(11):1387-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18361/abstract-text/15502598/pubmed\" id=\"15502598\" target=\"_blank\">",
"        15502598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horrigan JP and Barnhill LJ, &ldquo;Paroxetine-Pimozide Drug Interactions,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1994, 33(7):1060-1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keller MB, Ryan ND, Strober M, et al, &ldquo;Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 40(7):762-72.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lake MB, Birmaher B, Wassick S, et al, &ldquo;Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(1):35-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levinson-Castiel R, Merlob P, Linder N, et al, \"Neonatal Abstinence Syndrome After",
"      <i>",
"       in utero",
"      </i>",
"      Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2006, 160(2):173-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18361/abstract-text/16461873/pubmed\" id=\"16461873\" target=\"_blank\">",
"        16461873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mancini C, Van Ameringen M, Oakman JM, et al, &ldquo;Serotonergic Agents in the Treatment of Social Phobia in Children and Adolescents: A Case Series,&rdquo;",
"      <i>",
"       Depress Anxiety",
"      </i>",
"      , 1999, 10(1):33-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markel H, Lee A, Holmes RD, et al, &ldquo;LSD Flashback Syndrome Exacerbated by Selective Serotonin Reuptake Inhibitor Antidepressants in Adolescents,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(5 Pt 1):817-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rey-Sanchez F and Guitierrez-Cassares JR, &ldquo;Paroxetine in Children With Major Depressive Disorder: An Open Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(10):1443-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenberg DR, Stewart CM, Fitzgerald KD, et al, \"Paroxetine Open-Label Treatment of Pediatric Outpatients With Obsessive-Compulsive Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1999, 38(9):1180-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18361/abstract-text/10504818/pubmed\" id=\"10504818\" target=\"_blank\">",
"        10504818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safer DJ and Zito JM, \"Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1/2):159-69.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharp SC and Hellings JA, \"Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents: Practitioner Review,\"",
"      <i>",
"       Clin Drug Investig",
"      </i>",
"      , 2006, 26(5):247-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18361/abstract-text/17163258/pubmed\" id=\"17163258\" target=\"_blank\">",
"        17163258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snead RW, Boon F, and Presberg J, &ldquo;Paroxetine for Self-Injurious Behavior,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1994, 33(6):909-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stiskal JA, Kulin N, Koren G, et al, &ldquo;Neonatal Paroxetine Withdrawal Syndrome,&rdquo;",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2001, 84(2):F134-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, Berard R, Stein MB, et al, \"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine in Children and Adolescents With Social Anxiety Disorder,\"",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 2004, 61(11):1153-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18361/abstract-text/15520363/pubmed\" id=\"15520363\" target=\"_blank\">",
"        15520363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/59/18361/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12681 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18361=[""].join("\n");
var outline_f17_59_18361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709196\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206594\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054737\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054730\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206567\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206551\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874764\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054741\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054733\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054740\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206646\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206643\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054745\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054729\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054728\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206630\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206560\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054748\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206562\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206578\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054736\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054727\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054743\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054744\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054735\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054746\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12681\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12681|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=related_link\">",
"      Paroxetine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/12/17606?source=related_link\">",
"      Paroxetine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_59_18362="Autoimmune hemolytic anemia in children";
var content_f17_59_18362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autoimmune hemolytic anemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/59/18362/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/59/18362/contributors\">",
"     Russell E Ware, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/59/18362/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/59/18362/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/59/18362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/59/18362/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/59/18362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hemolytic anemia (AIHA) refers to a collection of disorders characterized by the presence of autoantibodies that bind to the patient's own erythrocytes, leading to premature red cell destruction. Specific characteristics of the autoantibodies, especially the type of antibody; its optimal binding temperature; and whether complement is fixed influence the clinical picture. In all cases of AIHA, however, the autoantibody leads to a shortened red blood cell survival (ie, hemolysis) and, when the rate of hemolysis exceeds the ability of the bone marrow to replace the destroyed red cells, to anemia and its attendant signs and symptoms.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical presentation, diagnosis, and treatment of AIHA in children are reviewed here. General approaches to the child with anemia and hemolytic anemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link\">",
"     \"Overview of hemolytic anemias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIHA is children is relatively rare, with an estimated annual incidence of 1 in 80,000 persons in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], rendering it more common than acquired aplastic anemia but less common than immune thrombocytopenia (ITP). AIHA can affect children of any race or nationality and can present in infancy, especially after an infection, and throughout childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Teenagers who present with AIHA are more likely to have an underlying systemic illness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simplistic classification scheme separates AIHA into a primary or a secondary process (",
"    <a class=\"graphic graphic_table graphicRef57399 \" href=\"UTD.htm?16/26/16811\">",
"     table 1",
"    </a>",
"    ). In a series of 265 children with AIHA, 37 percent were primary, 53 percent had an underlying immunological disorder including Evans&rsquo; syndrome, and 10 percent were post-infectious [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/9\">",
"     9",
"    </a>",
"    ]. At latest follow-up, ranging from 2.4 to 5.6 years among subtypes, 59 to 86 percent of the children were alive and off therapy, but only 33 to 44 percent of the children were in continuous complete remission. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary AIHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In primary AIHA, red blood cell autoantibodies are present and cause hemolytic anemia, but no evidence of an underlying systemic illness exists. Primary AIHA can be subclassified according to the characteristics of the erythrocyte autoantibodies and autoantigens (",
"    <a class=\"graphic graphic_table graphicRef55710 \" href=\"UTD.htm?12/53/13148\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Warm-reactive AIHA &ndash; The most common form of primary AIHA in children involves warm-reactive autoantibodies, usually IgG, that bind preferentially to the red cells at 37&ordm;C, fix complement in some cases, and lead to extravascular hemolysis mainly in the spleen, with resulting splenomegaly, jaundice, and anemia.",
"     </li>",
"     <li>",
"      Paroxysmal cold hemoglobinuria &ndash; A second category of primary AIHA, particularly common in children after a viral-like illness, is paroxysmal cold hemoglobinuria (PCH). PCH is characterized by IgG autoantibodies that bind preferentially at colder temperatures, fix complement efficiently, and cause intravascular hemolysis with hemoglobinemia, hemoglobinuria, and anemia.",
"     </li>",
"     <li>",
"      Cold agglutinin disease &ndash; The third major form of primary AIHA, cold agglutinin disease, is relatively rare in children, but can occur after Mycoplasma infection. In this disorder, IgM autoantibodies bind erythrocyte",
"      <span class=\"nowrap\">",
"       I/i",
"      </span>",
"      antigens at colder temperatures and fix complement, which leads to either complement-mediated intravascular hemolysis (like PCH) or immune-mediated extravascular clearance, mainly by hepatic macrophages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secondary AIHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIHA is considered to be a secondary process when the immune-mediated hemolytic anemia is only one manifestation of a broader systemic disorder. For example, secondary AIHA can occur in patients with systemic lupus erythematosus or other autoimmune disorders. Secondary AIHA can occur also in association with malignancy, immunodeficiency states, drug exposure, or following certain infections. Sometimes the AIHA is the initial manifestation of the underlying systemic illness, especially for unsuspected immunodeficiency states such as common variable immune deficiency (CVID). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link\">",
"     \"Common variable immunodeficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF RED CELL DESTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG-coated erythrocytes are removed primarily by the spleen, regardless of the presence of complement (",
"    <a class=\"graphic graphic_figure graphicRef64888 \" href=\"UTD.htm?37/9/38046\">",
"     figure 1",
"    </a>",
"    ). The amount of surface IgG is correlated with the rate of splenic clearance because Fc receptors on macrophages bind and phagocytose IgG-coated erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In contrast to IgG-mediated hemolysis, IgM-coated erythrocytes are cleared rapidly within the liver. The amount of complement affects the clearance of IgM-coated cells, with macrophage complement receptors responsible for binding and phagocytosis of erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/11,13\">",
"     11,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Warm-reactive AIHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In warm-reactive AIHA, the IgG autoantibodies coat autologous erythrocytes and may fix complement. These sensitized cells pass through the spleen and other parts of the reticuloendothelial system, where they interact with complement and Fc receptors on the macrophages. Erythrocytes may be fully ingested by macrophages; however, if only a portion of the surface membrane is removed, the erythrocyte reforms into a spherocyte, which is identifiable on the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"     picture 1",
"    </a>",
"    ). For IgG-coated erythrocytes, the majority of immune clearance occurs within the spleen (ie, extravascular hemolysis), (",
"    <a class=\"graphic graphic_figure graphicRef64888 \" href=\"UTD.htm?37/9/38046\">",
"     figure 1",
"    </a>",
"    ), which does not lead to hemoglobinemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemoglobinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cold-reactive AIHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cold agglutinin disease or paroxysmal cold hemoglobinuria, the autoreactive antibody binds preferentially at 4&ordm;C and fixes complement efficiently. At normal body temperature, virtually no antibody is identifiable on the cell surface, but complement components, particularly C3b, can be identified using the antiglobulin (formerly called Coombs') reagent. If complement is activated to completion on the cell surface, erythrocytes will hemolyze intravascularly, resulting in hemoglobinemia and hemoglobinuria (",
"    <a class=\"graphic graphic_figure graphicRef64888 \" href=\"UTD.htm?37/9/38046\">",
"     figure 1",
"    </a>",
"    ). When complement is deposited on the red cell but not fully activated to the point of cell lysis, macrophages within the reticuloendothelial system bind the erythrocytes using complement receptors and engulf them in a manner similar to warm-reactive AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/14\">",
"     14",
"    </a>",
"    ]. However, complement-coated erythrocytes are cleared by macrophages primarily within the liver rather than the spleen (",
"    <a class=\"graphic graphic_figure graphicRef64888 \" href=\"UTD.htm?37/9/38046\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with AIHA present with signs and symptoms referable to anemia, including weakness, fatigue, shortness of breath, dizziness, pallor, jaundice,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dark urine. Less commonly, children with AIHA will present with abdominal pain or fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patient history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with primary AIHA usually has a benign previous medical history and a negative family history. The review of systems should focus on any recent acute infectious illness, signs and symptoms of a potential underlying systemic illness, and concurrent medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, the child with AIHA often will be pale and jaundiced, especially apparent in the conjunctivae and palms. The presence of skeletal abnormalities suggests the presence of congenital disorders such as Blackfan-Diamond anemia, Fanconi anemia, constitutional aplastic anemia, or beta thalassemia major. Often, tachycardia is present, as is a systolic flow murmur, reflecting a high-output anemic state; however, cardiovascular compromise (eg, congestive failure) is uncommon unless the hemoglobin concentration is &lt;5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The liver and spleen may be palpable, but the presence of massive organomegaly or lymph node enlargement should suggest another disorder such as malignancy (eg, leukemia, lymphoma) or infection (eg, HIV, malaria, tuberculosis).",
"   </p>",
"   <p>",
"    In the classic, uncomplicated case of warm-reactive AIHA, the child will appear jaundiced, but excessive bilirubin will not be present in the urine (ie, hemolytic or \"acholuric\" jaundice). The passage of dark urine in AIHA, in colors ranging from gold to red to black, usually signifies the presence of hemoglobin (hemoglobinuria), secondary to intravascular hemolysis, and is more suggestive of cold-reactive AIHA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reasonable and appropriate initial laboratory evaluation of the child with AIHA is quite modest. Always, a complete blood count should be ordered, and the hemoglobin concentration may be surprisingly low (&lt;7",
"    <span class=\"nowrap\">",
"     gm/dL).",
"    </span>",
"    Red blood cell indices (eg, mean cellular volume [MCV] or red cell distribution width [RDW]) generally are not helpful in establishing the diagnosis. However, abnormalities of the RBC indices occasionally can be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the presence of a cold or warm agglutinin, the red cells may pass through the automated counter in small clumps, rather than one at a time, resulting in a spuriously increased mean corpuscular volume (MCV). Due to RBC clumping, the reported MCV will sometimes be at non-physiologic or implausible levels such as 180 to 250 fL. Examination of the peripheral smear can determine whether this phenomenon is present (",
"      <a class=\"graphic graphic_picture graphicRef50522 \" href=\"UTD.htm?15/10/15527\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=see_link&amp;anchor=H14#H14\">",
"       \"Macrocytosis\", section on 'Spurious macrocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the presence of large numbers of spherocytes, the mean corpuscular hemoglobin concentration (MCHC) may be elevated, usually to levels &gt;36",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      This finding is not specific to AIHA, however, since it also is present in patients with congenital (hereditary) spherocytosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The leukocyte count and platelet count should be normal or elevated; the presence of leukopenia or thrombocytopenia suggests the presence of a bone marrow failure syndrome (eg, aplastic anemia), microangiopathic hemolytic anemia (eg, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura), or bone marrow suppression secondary to an active infection.",
"   </p>",
"   <p>",
"    In rare instances, autoantibodies against other formed elements in the blood may be present in a patient with AIHA. In such cases, the patient will present with direct antiglobulin test (DAT, formerly called Coombs) positive AIHA, along with thrombocytopenia, and, more rarely, neutropenia (Evans syndrome). (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Evans syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Reticulocyte count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute reticulocyte count usually is elevated from the normal value of 50 to 75 x",
"    <span class=\"nowrap\">",
"     10(3)/microL",
"    </span>",
"    and may reach values as high as 600 to 800 x",
"    <span class=\"nowrap\">",
"     10(3)/microL.",
"    </span>",
"    A low reticulocyte count occasionally is encountered and may reflect a concomitant accelerated immune-mediated destruction of red blood precursors within the marrow, a temporary suppression of bone marrow activity secondary to infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a delayed bone marrow response to the hemolytic event [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Peripheral blood smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the peripheral blood smear is a critical part of the patient workup in AIHA. Numerous small spherocytes usually are present, especially in warm-reactive AIHA (",
"    <a class=\"graphic graphic_picture graphicRef53523 \" href=\"UTD.htm?32/10/32935\">",
"     picture 3",
"    </a>",
"    ). A few teardrop shaped red cells or red cell fragments (schistocytes) may be present, but spherocytes should predominate. In the presence of especially severe hemolysis, red blood cell precursors, such as normoblasts, may be present in the circulation (",
"    <a class=\"graphic graphic_picture graphicRef50601 \" href=\"UTD.htm?9/21/9552\">",
"     picture 4",
"    </a>",
"    ). The presence of clumped or agglutinated red cells suggests the presence of a cold-reactive AIHA (",
"    <a class=\"graphic graphic_picture graphicRef50522 \" href=\"UTD.htm?15/10/15527\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polychromasia, reflecting an increased number of circulating young red cells (reticulocytes), is commonly observed because reticulocytes are released from the bone marrow to compensate for accelerated erythrocyte destruction (",
"    <a class=\"graphic graphic_picture graphicRef53523 \" href=\"UTD.htm?32/10/32935\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"UTD.htm?31/9/31895\">",
"     picture 5",
"    </a>",
"    ). Howell-Jolly bodies may be seen on the blood smear, reflecting accelerated erythropoiesis or a prior splenectomy for a hemolytic process (",
"    <a class=\"graphic graphic_picture graphicRef60588 \" href=\"UTD.htm?38/45/39638\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the bone marrow is typically not needed to establish the diagnosis of AIHA, unless there are unusual characteristics to the medical history or physical examination. In some cases, however, bone marrow aspiration may be helpful to exclude a malignant process, myelodysplasia, or one of the bone marrow failure syndromes. In AIHA, the marrow aspirate usually reveals intense erythroid hyperplasia (",
"    <a class=\"graphic graphic_picture graphicRef75057 \" href=\"UTD.htm?42/36/43589\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68933 \" href=\"UTD.htm?39/7/40050\">",
"     picture 8",
"    </a>",
"    ), whereas isolated erythroid hypoplasia or aplasia may signify the presence of acquired pure red cell aplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H10#H10\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Acquired pure red cell aplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the urine always should be performed. In children with extravascular hemolysis, the urinalysis may be completely normal. In children with intravascular hemolysis, hemoglobin is released into the plasma, then cleared through the kidneys into the urine. When hemoglobinuria is present, urine dipstick testing will identify the presence of blood, but microscopic examination will reveal no red blood cells. Chronic hemoglobinuria also will lead to hemosiderin accumulation in uroepithelial cells, which can be detected as a positive iron stain of cells in the urinary sediment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Direct antiglobulin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important and useful laboratory test to establish the diagnosis of AIHA is the direct antiglobulin test (DAT), formerly known as the Coombs test. The DAT identifies the presence of antibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complement on the surface of the erythrocyte; results are scored in a semiquantitative manner, based on the amount of red cell agglutination.",
"   </p>",
"   <p>",
"    Appropriate characterization of the erythrocyte antibodies includes determination of the isotype, the presence of complement, thermal reactivity of the antibody, and the binding specificity to erythrocyte antigens. In less than 5 percent of childhood cases, the DAT is negative despite good clinical evidence for the presence of warm AIHA. In such cases, the amount of IgG on the erythrocyte may be below the threshold for detection by standard Coombs testing. Alternatively, an IgA autoantibody [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/16\">",
"     16",
"    </a>",
"    ] or even a warm-reactive IgM autoantibody may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/17\">",
"     17",
"    </a>",
"    ]. Because IgM and IgA antibodies are not reactive with the standard Coombs reagent, specific research reagents and techniques must be used for their identification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected measurement of serum chemistries should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total bilirubin is elevated in most patients with AIHA because of accelerated erythrocyte destruction; it should primarily be in the unconjugated (ie, indirect) form. Elevated direct (conjugated) bilirubin suggests intrinsic liver disease.",
"     </li>",
"     <li>",
"      Elevated serum concentrations of lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) are seen in AIHA, reflecting the presence of hemolysis, especially intravascular hemolysis. Alanine amino transferase (ALT) and other hepatic enzymes should not be elevated in AIHA.",
"     </li>",
"     <li>",
"      Serum haptoglobin, which binds free plasma hemoglobin, will be low in most cases of AIHA. However, haptoglobin is not synthesized well in young infants; it also is an acute phase reactant, and its concentration may be elevated in the presence of infection or inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/18\">",
"       18",
"      </a>",
"      ]. For these reasons, quantitation of the haptoglobin level may not be helpful in the evaluation of a young patient with AIHA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     IMMUNOHEMATOLOGIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with laboratory results consistent with hemolysis and a positive DAT (Coombs test), immunohematologic studies are performed to categorize the type of AIHA. In many institutions, this testing is performed by the transfusion service, Blood Bank, or hospital laboratory service. The laboratory should confirm the diagnosis of AIHA with the positive DAT (Coombs test). However, additional factors can affect the location and type of hemolysis in AIHA (",
"    <a class=\"graphic graphic_table graphicRef63603 \" href=\"UTD.htm?15/16/15627\">",
"     table 3",
"    </a>",
"    ). In most pediatric cases of AIHA, the pathogenic antibody is identified as an IgG molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/5,19,20\">",
"     5,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, IgG autoantibodies bind to red cell antigens optimally at 37&ordm;C; hence, the descriptive term \"warm-reactive\" autoantibodies. The presence of IgG on the erythrocyte is sufficient evidence for the presence of an IgG autoantibody; simultaneous detection of complement indicates that the antibody can fix complement as well. The ability of an erythrocyte autoantibody to fix complement plays a critical role in the pathophysiology of immune clearance and the clinical manifestations of hemolysis, as complement augments the destructive effects of the autoantibody.",
"   </p>",
"   <p>",
"    The presence of complement alone (with no IgG detected) suggests a cold-reactive autoantibody that fixes complement at lower temperatures but binds poorly to erythrocytes at warmer temperatures. When this occurs, the child's serum should be tested for cold-reactive IgG Donath-Landsteiner autoantibodies characteristic of paroxysmal cold hemoglobinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/21\">",
"     21",
"    </a>",
"    ]. These cold-reactive IgG autoantibodies have optimal binding at 4&ordm;C, and often the DAT is negative or demonstrates only the presence of complement. To detect cold-reacting antibodies, special testing must be performed that includes maintaining the temperature of the blood at 37&ordm;C during its collection and transport to the laboratory, before separation of serum for specific testing.",
"   </p>",
"   <p>",
"    IgM autoantibodies typically have optimal binding to erythrocytes at 0 to 4&ordm;C; hence, these are called cold-reactive antibodies or cold agglutinins. Cold-reactive IgM autoantibodies in the serum are characteristic of cold agglutinin disease, and they often follow a defined infection with agents such as Mycoplasma pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/22\">",
"     22",
"    </a>",
"    ]. The IgM autoantibody binds optimally in cooler temperatures, but complement activation proceeds optimally at warmer temperatures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antigenic reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A \"nonspecific\" or \"panreactive\" pattern of reactivity is sometimes reported, which suggests that the autoantibody is binding to a common or universal RBC surface antigen, such as the Rh locus. In such cases, the patient's antibody will react with all red cells with the exception of those from patients with Rh (null). Reactivity against a particular Rh antigen such as c or e is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/23\">",
"     23",
"    </a>",
"    ], but it is not common. Reactivity with the ABO blood group antigens [22] or other major systems such as Lewis or Kell are extremely rare [19,23]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Characteristics of the antigens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, IgM autoantibodies frequently have reactivity against polysaccharides on the red cell surface rather than surface proteins. The",
"    <span class=\"nowrap\">",
"     I/i",
"    </span>",
"    surface structure is a prototypic polysaccharide autoantigen on the red cell surface and is the target of many IgM antibodies that develop in response to infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition to the important",
"    <span class=\"nowrap\">",
"     I/i",
"    </span>",
"    surface antigens, other autoantigens, including the polysaccharide P autoantigen involved in paroxysmal cold hemoglobinuria, also have been reported in IgM-mediated AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determination of the antigenic specificity of erythrocyte autoantibodies is important for two reasons. First, an autoantibody with a \"panreactive\" pattern will bind all cells, which renders finding fully compatible blood for transfusion difficult or impossible. Second, identification of the antigenic specificity also can help predict intravascular lysis caused by complement activation. If the antigen is within the Rh complex, complement-mediated intravascular hemolysis is unlikely. The P antigen system, in contrast, is capable of binding sufficient IgG antibody to allow Donath-Landsteiner antibodies to fix complement completely and allow intravascular lysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child who presents with AIHA usually has clinical, physical, and laboratory evidence of hemolytic anemia, which involves increased erythrocyte destruction and a compensatory reticulocytosis. The main differential diagnosis includes causes of non-immune hemolytic anemia, such as intrinsic red cell membrane or enzyme defects, as well as extrinsic causes of hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link\">",
"     \"Overview of hemolytic anemias in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"    </a>",
"    .) The presence or absence of the findings listed below may be of some help in devising an appropriate differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Spherocytes and other red cell alterations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spherocytosis (HS) can be easily confused with AIHA because of the presence of spherocytes and reticulocytosis in both disorders (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"     picture 1",
"    </a>",
"    ). A positive family history may be obtained in the former and usually is negative in the latter. In addition, the direct antiglobulin test (formerly called the Coombs test) is positive in AIHA and negative in HS.",
"   </p>",
"   <p>",
"    Patients with microangiopathic hemolytic anemia, such as occurs in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, may have spherocytes, but more typically they have red cell fragments (schistocytes) in the circulation, along with severe thrombocytopenia, and varying degrees of renal insufficiency and neurologic changes (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia can result from increased erythrocyte destruction (hemolysis), but it can also be the result of decreased erythrocyte production, such as congenital bone marrow failure syndromes, acquired aplastic anemia, or transient red cell aplasia. In contrast to the hemolytic anemias, these disorders typically have a low reticulocyte count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    .) Other important causes of anemia which should be considered in the anemic child include chronic severe iron deficiency, lead poisoning, and alpha or beta-thalassemia trait. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .) Finally, chronic blood loss, usually gastrointestinal, leading to symptomatic anemia is detectable by stool guaiac testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dark urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dark urine caused by the presence of hemoglobin in the urine (hemoglobinuria) can be confused with concentrated urine or the presence of bilirubin or porphyrin precursors in the urine. Urinalysis can distinguish these conditions from true hemoglobinuria, which causes a positive dipstick test for blood and protein without the presence of red blood cells on microscopic analysis. Hemoglobinuria is uncommon and indicates intravascular hemolysis from pathological states including AIHA, glucose 6-phosphate dehydrogenase (G6PD) deficiency, or rarely paroxysmal nocturnal hemoglobinuria (PNH). Myoglobinuria from rapid and extensive muscle breakdown can mimic hemoglobinuria on urinalysis, but the two pigments can be distinguished chemically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .) Hemolytic anemia can occur in several of the porphyrias; specialized testing is required in order to make this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child who presents with jaundice must be evaluated for the presence of underlying liver disease. Measurement of transaminases and coagulation factors can be useful in assessing hepatic function. Serologic testing for hepatitis viruses, cytomegalovirus, and Epstein-Barr virus may be prudent if liver disease is suspected. In hemolytic anemia, the indirect (unconjugated) bilirubin fraction is typically elevated. In contrast, an elevated direct (conjugated) bilirubin level suggests intrinsic liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SECONDARY AUTOIMMUNE HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIHA occurring in association with another systemic illness is referred to as secondary AIHA (",
"    <a class=\"graphic graphic_table graphicRef57399 \" href=\"UTD.htm?16/26/16811\">",
"     table 1",
"    </a>",
"    ). Children with secondary AIHA often have a broad dysregulation of their immune system. Particularly in older children, a substantial number of cases of warm-reactive AIHA actually are secondary AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/20\">",
"     20",
"    </a>",
"    ]. This observation demonstrates the need to consider the possibility of an underlying systemic illness in all children with AIHA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most common form of secondary AIHA in older children occurs in association with a broad autoimmune disease such as systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27303?source=see_link&amp;anchor=H7#H7\">",
"     \"Hematologic problems in children and adolescents with systemic lupus erythematosus\", section on 'Autoimmune hemolytic anemia'",
"    </a>",
"    .) Other systemic autoimmune or inflammatory disorders (eg, Sjogren syndrome, scleroderma, rheumatoid arthritis, dermatomyositis, ulcerative colitis, autoimmune thyroiditis) also have been associated with AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/20,28\">",
"     20,28",
"    </a>",
"    ]. Children with these disorders probably have a genetic susceptibility with immune dysregulation, which leads to the expansion and proliferation of autoreactive B lymphocytes. Often there is a family history of autoimmune disorders (not necessarily immune-mediated hematologic conditions) such as lupus, thyroid disease, or rheumatoid arthritis.",
"   </p>",
"   <p>",
"    Children with congenital immunodeficiency also can develop secondary AIHA, almost certainly caused by altered immune regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/29\">",
"     29",
"    </a>",
"    ]. AIHA can present in children as the initial manifestation of an unsuspected congenital immunodeficiency disorder, particularly common variable immune deficiency (CVID). Children with acquired immunodeficiency, including those infected with the human immunodeficiency virus, can develop erythrocyte autoantibodies and secondary AIHA caused by polyclonal B lymphocyte activation and poor immune regulation by T lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Evans syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A special association exists between AIHA and other autoimmune cytopenias, especially thrombocytopenia. When a child has concurrent AIHA and thrombocytopenia (ITP), the disorder usually is referred to as Evans syndrome. Some children with Evans syndrome also have autoimmune neutropenia. In two large reviews, the clinical course of Evans syndrome was found to be chronic and relapsing; treatment (eg, steroids, intravenous immunoglobulin,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , chemotherapy) has been similar to, although less satisfactory than, the treatment of patients with isolated AIHA or ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because many patients with Evans Syndrome have underlying immune dysregulation, it is appropriate to consider Evans syndrome in young patients with AIHA. A variety of immunoregulatory abnormalities in Evans syndrome have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/32\">",
"     32",
"    </a>",
"    ], but no specific underlying immune defect has been identified. Autoantibodies apparently are directed against specific antigens on each of the various blood cell types, without cross-reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/33\">",
"     33",
"    </a>",
"    ]. If Evans syndrome is suspected, it is important to rule out the presence of autoimmune lymphoproliferative syndrome (ALPS). In one study, as an example, 7 of 12 children with Evans syndrome had abnormal tests of T-cell function suggestive of ALPS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/34\">",
"     34",
"    </a>",
"    ]. Evans syndrome is also associated with common variable immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link&amp;anchor=H10572417#H10572417\">",
"     \"Common variable immunodeficiency in children\", section on 'Autoimmune disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary AIHA can occur in the setting of malignancy, occasionally presenting before the underlying diagnosis has been made. Adults with chronic lymphocytic leukemia, lymphoma, or multiple myeloma may have erythrocyte autoantibodies in association with their abnormal B lymphocyte clone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. AIHA also can occur in children with Hodgkin disease, acute leukemia, myelodysplasia, or following allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The pathogenesis of the erythrocyte autoantibodies in association with cancer is unknown, but an underlying immune deficiency may lead to both autoimmune phenomena and malignancy. Particularly for children with AIHA secondary to an underlying immune deficiency such as CVID or ALPS, malignancy can present during or even after the hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is another important cause of AIHA. Most children who present with PCH have had a recent viral-like illness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/4,40\">",
"     4,40",
"    </a>",
"    ], but the specific pathogen usually is not identified. In the past, PCH most commonly developed in patients with syphilis; this cause is rarely observed today. Occasionally a specific infectious agent, including Mycoplasma pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/41\">",
"     41",
"    </a>",
"    ], Epstein-Barr virus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], measles, varicella, mumps, and rubella, triggers AIHA. Most of these infections are associated with IgM autoantibodies with a specificity for the",
"    <span class=\"nowrap\">",
"     I/i",
"    </span>",
"    polysaccharide antigen system on red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/22\">",
"     22",
"    </a>",
"    ], although reactivity with the P polysaccharide antigen has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Reactivity of anti-I red cell antibodies with mycoplasma antigens suggests that the erythrocyte autoantibodies may result from immunologic cross-reactivity. Most cold agglutinins associated with varicella infection have anti-Pr activity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute bacterial infections also can cause hemolytic anemia, but from a different mechanism. The T antigen on the erythrocyte surface is considered a \"cryptic\" antigen and normally is not available for binding. Infection with bacteria harboring neuraminidase (sialidase) activity, such as Clostridial or Pneumococcal species, leads to sialic acid removal and subsequent exposure of the T antigen. Many persons have naturally occurring cold-reactive IgM antibodies with anti-T specificity, allowing hemolysis to result in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/47\">",
"     47",
"    </a>",
"    ]. Concomitant G6PD-deficiency can exacerbate hemolytic anemia during infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not common in children, erythrocyte autoantibodies and hemolysis in association with drug exposure may cause secondary AIHA. This process was described classically after therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/10/20645?source=see_link\">",
"     methyldopa",
"    </a>",
"    , but red cell autoantibodies have been reported in association with many different pharmaceutical agents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/48\">",
"     48",
"    </a>",
"    ]. Medications that are particularly important in causing AIHA in children include penicillins, cephalosporins,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11382?source=see_link\">",
"     probenecid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    . The mechanism of drug-induced hemolytic anemia typically results from generation of autoantibodies, although the drug may be required to form a hapten or even a ternary complex with the erythrocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Drug-related immune hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal treatment of a child with AIHA depends initially upon the severity of the anemia, the signs and symptoms, and the characteristics of the autoantibodies. In the setting of severe intravascular hemolysis, for example, maintaining a good renal blood flow and urine output is imperative. The characteristics of the antibodies are paramount; for example, children with cold-reactive autoantibodies should avoid cold stimuli to prevent autoantibody binding, whereas those with warm-reactive autoantibodies usually respond best to corticosteroids. The following table includes treatment modalities that are useful in children with primary AIHA, emphasizing the differences among the three major clinical conditions: warm-reactive AIHA, paroxysmal cold hemoglobinuria, and cold agglutinin disease (",
"    <a class=\"graphic graphic_table graphicRef55710 \" href=\"UTD.htm?12/53/13148\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of AIHA, transfusions can be avoided and specific therapy can be instituted, depending upon the particular type.",
"   </p>",
"   <p>",
"    However, if the anemia is causing cardiovascular compromise (usually when the hemoglobin concentration is below 5",
"    <span class=\"nowrap\">",
"     gm/dL),",
"    </span>",
"    strong consideration must be given to transfusing the patient with erythrocytes to provide the needed oxygen-carrying capacity. Administering a transfusion to a child with erythrocyte autoantibodies may seem complicated and intimidating, but it also may be life-saving. Although transfusions can lead to additional hemolysis, it must be emphasized that, despite the risks, transfusion therapy should not be withheld from a patient with AIHA and life-threatening anemia.",
"   </p>",
"   <p>",
"    Identification of compatible erythrocytes to transfuse into a child with AIHA can be problematic. The Transfusion Service or Blood Bank may need extra serum and cells for testing, well in advance of the possible erythrocyte transfusion. If the autoantibody is reactive with all donor units (ie, the antibody is \"pan-reactive\"), no units of blood will be deemed \"fully compatible\" based on the crossmatch, although certain units may be designated \"least incompatible\" with the patient's serum. Available adsorption techniques to remove autoantibodies may allow the identification of clinically important alloantibodies that also may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link&amp;anchor=H19#H19\">",
"     \"The incompatible crossmatch\", section on 'AIHA and concurrent alloantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the actual erythrocyte transfusion is given, acute symptomatic transfusion reactions are not common, even when transfusing \"least incompatible\" units of blood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/51\">",
"     51",
"    </a>",
"    ]. Because transfused donor cells generally survive in patients with AIHA similar to the patient's own erythrocytes, transfusion should be helpful, even if the transfused erythrocytes last in the circulation for only a short period of time. On the rare occasion when a transfusion results in more severe hemolysis, with substantial hemoglobinemia and hemoglobinuria, vigorous hydration will help prevent renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the autoantibodies fix complement and cause intravascular hemolysis, a prudent procedure is to begin the transfusion at a slow rate, checking both plasma and urine samples periodically for the presence of free hemoglobin. Warming the blood during infusion is useful for patients with cold-reactive autoantibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link&amp;anchor=H23#H23\">",
"     \"The incompatible crossmatch\", section on 'Clinical management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids remain the best primary therapy for warm-reactive AIHA, particularly for children with IgG antibodies, as steroids interfere with the basic pathophysiology and immune destruction of erythrocytes. Corticosteroids inhibit the Fc receptor-mediated clearance of sensitized erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/52\">",
"     52",
"    </a>",
"    ], which likely accounts for their rapid effect within 24 to 48 hours. Steroids may also diminish the production of autoantibodies, but this effect may require several weeks.",
"   </p>",
"   <p>",
"    For the very anemic child with warm-reactive AIHA, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    should be administered every 6 hours at a dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for the first 24 to 72 hours. Oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    at a total dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day is then used after the child is more clinically stable. Typically, high doses are used for two to four weeks, followed by a slow taper over two to six months, based upon the hemoglobin concentration, reticulocyte count, and direct antiglobulin test results. Using this approach has resulted in an overall response rate of approximately 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, children with PCH usually have a self-limited hemolytic process, but may need a short course of corticosteroids to reduce hemolysis and improve anemia. Less commonly, corticosteroids may be beneficial in cold-agglutinin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Warming",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with cold-reactive antibodies, keeping the patient warm at all times is important and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoiding exposure to cold environments (eg, Radiology suite)",
"     </li>",
"     <li>",
"      Warming the patient's room with additional space heaters, if needed",
"     </li>",
"     <li>",
"      Use of socks and warm clothing",
"     </li>",
"     <li>",
"      Using a blood warming apparatus during any intravenous infusions and especially during any transfusion of fluids which have been refrigerated, such as erythrocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IGIV, IVIG) induces a potent blockade of the reticuloendothelial system [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/55\">",
"     55",
"    </a>",
"    ] and offers an attractive therapeutic option for adults with AIHA. Unfortunately, most children with AIHA do not respond to IGIV therapy, even at the very high doses (1.0",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    per day for five days) advocated in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/56\">",
"     56",
"    </a>",
"    ]. At this time, IGIV should",
"    <strong>",
"     not",
"    </strong>",
"    be considered standard therapy for children with AIHA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Exchange transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exchange transfusion is another attractive therapeutic option for AIHA because the autoantibodies, complement components, and coated erythrocytes all can be removed from the patient simultaneously. More commonly, however, plasmapheresis or plasma exchange is used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/57\">",
"     57",
"    </a>",
"    ], even in very small infants [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12597?source=see_link\">",
"     \"Indications for therapeutic plasma exchange\"",
"    </a>",
"    .) Patients with IgM autoantibodies respond better to plasmapheresis than do those with IgG autoantibodies because the larger IgM molecules are found mostly within the intravascular space [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In addition, at warm temperatures IgM autoantibodies are bound less tightly to red cells than are IgG autoantibodies, allowing them to be removed more easily by plasmapheresis. In contrast, IgG autoantibodies diffuse into the extravascular space, so that plasmapheresis removes only a portion of the total IgG autoantibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H957606\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    (Rituxan&reg;) has been successfully used to treat some children with either primary or secondary AIHA that are refractory to or dependent on corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. This is an off-label use of rituximab, based on single-arm, non-randomized trials. In one retrospective study, rituximab alone or in combination with other immunosuppressive agents induced a partial or complete remission in 13 of 17 children with Evans syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/64\">",
"     64",
"    </a>",
"    ]. Our own experience with rituximab for childhood AIHA is encouraging, with few side effects following four weekly infusions (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose)",
"    </span>",
"    and good therapeutic responses. It is likely that rituximab will become more widely used as a means to postpone or even avoid splenectomy in AIHA, but its risks and benefits have not been clearly defined to date. It is our practice to offer a trial of rituximab before splenectomy in patients that are refractory to or dependent on corticosteroids.",
"   </p>",
"   <p>",
"    Although hematological responses are encouraging, profound hypogammaglobulinemia and prolonged absence of circulating B-cells will occur after",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/61\">",
"     61",
"    </a>",
"    ]. Intravenous immunoglobulin may be useful as replacement therapy after rituximab use [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Immunosuppressive and cytotoxic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy is the time-honored therapy for the child with chronic or recalcitrant AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/53,66\">",
"     53,66",
"    </a>",
"    ] and works by removing the main site of erythrocyte destruction (",
"    <a class=\"graphic graphic_figure graphicRef64888 \" href=\"UTD.htm?37/9/38046\">",
"     figure 1",
"    </a>",
"    ). Splenectomy also may benefit the patient with AIHA by removing a major site of autoantibody production, similar to its effects in immune thrombocytopenia (ITP).",
"   </p>",
"   <p>",
"    Children with IgG autoantibodies respond better to splenectomy than do those with IgM autoantibodies, but the success of splenectomy cannot be predicted before surgery. Specifically, radiolabeled red cell survival studies are not reliable indicators of the clinical response to splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=see_link&amp;anchor=H10#H10\">",
"     \"Red blood cell survival: Normal values and measurement\", section on 'Sites of red blood cell destruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 52 patients with AIHA who underwent splenectomy, with absent surgical mortality and low morbidity, an excellent response was reported in 64 percent, and an improved status in another 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/68\">",
"     68",
"    </a>",
"    ]. However, splenectomy is to be avoided in young children whenever possible because of the possibility of post-splenectomy sepsis caused by encapsulated bacterial organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before splenectomy is performed (whenever possible), or shortly thereafter, children should receive immunization with both the polysaccharide vaccine (Pneumovax&reg;) and a protein-conjugated polyvalent vaccine (Prevnar&reg;) to enhance their humoral immune response against Streptococcus pneumoniae. They also should receive anti-Haemophilus and meningococcal vaccines at this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Immunizations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Post-splenectomy care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who undergo splenectomy should receive penicillin twice a day for at least two years after surgery; many clinicians prefer life-long post-splenectomy penicillin prophylaxis.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     Erythromycin",
"    </a>",
"    can be used if the patient is allergic to penicillin. After splenectomy, children with fever higher than 38.5&ordm;C (101.5&ordm;F) should seek",
"    <strong>",
"     immediate",
"    </strong>",
"    medical attention for the possibility of bacterial sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H11#H11\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the child with refractory AIHA, more aggressive therapy may be required to alleviate the symptoms of anemia and to help the child achieve a more normal lifestyle. The long-term use of corticosteroids or immunoglobulin generally is unacceptable because of side effects, costs, and inconvenience. No simple algorithm can be proposed that is correct for all patients; instead, the clinician should individualize therapy for each patient, depending upon the hematologic response and side-effects. Several treatment options are available for such children, although each is less effective than either corticosteroids or splenectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Danazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective immunomodulatory agent is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5301?source=see_link\">",
"     danazol",
"    </a>",
"    , a semisynthetic androgen that can reduce cell-bound IgG and complement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/69\">",
"     69",
"    </a>",
"    ] and decrease IgG production [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/70\">",
"     70",
"    </a>",
"    ]. The primary adverse side effects of danazol are elevations in the hepatic transaminases and mild masculinizing effects; as a result, females typically do not tolerate use of this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is another immunosuppressive agent that primarily affects T lymphocyte helper function and thereby diminishes autoantibody synthesis. Clinical responses to azathioprine may require more than two to three months of therapy, with dose escalation to 150 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclosporin A is another immunosuppressive agent that also primarily affects T lymphocytes. Long-term use of cyclosporin has been associated with nephrotoxicity, hypertension, and a risk of second malignancy, and it should be reserved for children with refractory AIHA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Cytotoxic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic agents that can reduce autoantibody formation include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7975?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Although few data exist on their efficacy in children with AIHA, these agents should be considered for the refractory patient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/59/18362/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. These agents generally are myelosuppressive and potentially mutagenic, and they should be used with caution in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune hemolytic anemia (AIHA) is caused by anti-erythrocyte autoantibodies that lead to premature red cell destruction. If the rate of hemolysis exceeds the ability of the bone marrow to replace the destroyed red cells, this leads to anemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In primary AIHA, there is no evidence of an underlying systemic illness. Primary AIHA can be subclassified according to the characteristics of the erythrocyte autoantibodies, particularly the temperature at which they bind to red cells (warm-reactive versus cold-reactive AIHA). There are three major categories of primary AIHA (",
"      <a class=\"graphic graphic_table graphicRef55710 \" href=\"UTD.htm?12/53/13148\">",
"       table 2",
"      </a>",
"      ): (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Primary AIHA'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Warm-reactive AIHA &ndash; The most common form in children involves warm-reactive autoantibodies, which lead to extravascular hemolysis mainly in the spleen, with resulting splenomegaly, jaundice, and anemia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Warm-reactive AIHA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paroxysmal cold hemoglobinuria (PCH) &ndash; This form of primary AIHA is characterized by cold-reactive autoantibodies that cause intravascular hemolysis with hemoglobinemia, hemoglobinuria, and anemia. It is particularly common in children after a viral-like illness.",
"     </li>",
"     <li>",
"      Cold agglutinin disease &ndash; This form is relatively rare in children, but can occur after Mycoplasma infection. It is mediated by cold-reactive IgM autoantibodies causing intravascular hemolysis or immune-mediated extravascular clearance in the liver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary AIHA can occur in patients with systemic lupus erythematosus or other autoimmune disorders, immunodeficiency states, drug exposure, malignancy, or following certain infections (",
"      <a class=\"graphic graphic_table graphicRef57399 \" href=\"UTD.htm?16/26/16811\">",
"       table 1",
"      </a>",
"      ). Particularly in older children, a substantial number of cases of warm-reactive AIHA actually are secondary AIHA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with AIHA present with signs and symptoms referable to anemia, including weakness, shortness of breath, dizziness, pallor, jaundice,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dark urine. The presence of dark urine in AIHA suggests intravascular hemolysis, and is more suggestive of cold-reactive AIHA. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial laboratory evaluation of a child with suspected AIHA should consist of a complete blood count, reticulocyte count, direct antiglobulin test (DAT, formerly known as the Coombs test), urinalysis for hemoglobinuria, and microscopic examination of the blood smear. In cases of AIHA, the DAT should be positive, indicating the presence of IgG autoantibodies. Elevations of unconjugated bilirubin, lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) are common but not diagnostic; elevations of alanine aminotransferase (ALT) are not. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with laboratory results consistent with hemolysis and a positive DAT (Coombs test), immunohematologic studies should be performed to categorize the type of AIHA, and include antibody isotype (IgG, IgM, or IgA), titer, and thermal reactivity (",
"      <a class=\"graphic graphic_table graphicRef63603 \" href=\"UTD.htm?15/16/15627\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Immunohematologic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of secondary AIHA should be considered particularly in patients with thrombocytopenia (Evans syndrome), marked hepatosplenomegaly, a history of recent viral infection, or use of certain drugs (eg, one of several antibiotics, or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11382?source=see_link\">",
"       probenecid",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Secondary autoimmune hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different treatments are indicated for each of the three major types of primary AIHA (warm-reactive, paroxysmal cold hemoglobinuria, and cold agglutinin disease) (",
"      <a class=\"graphic graphic_table graphicRef55710 \" href=\"UTD.htm?12/53/13148\">",
"       table 2",
"      </a>",
"      ). Children with cold-reactive autoantibodies should avoid cold stimuli to prevent autoantibody binding, whereas those with warm-reactive autoantibodies usually respond best to corticosteroids. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Schreiber AD, Rosse WF, Frank MM. Autoimmune hemolytic anemia. In: Samter's Immunologic Diseases, 5th, Frank MM, Austen KF, Claman HN, Unanue ER (Eds), Little, Brown, and Company, Boston 1995. p.903.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/2\">",
"      Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002; 69:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/3\">",
"      Habibi B, Homberg JC, Schaison G, Salmon C. Autoimmune hemolytic anemia in children. A review of 80 cases. Am J Med 1974; 56:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/4\">",
"      Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis associated with Donath-Landsteiner antibodies. Acta Haematol 1982; 68:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/5\">",
"      Sokol RJ, Hewitt S, Stamps BK, Hitchen PA. Autoimmune haemolysis in childhood and adolescence. Acta Haematol 1984; 72:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/6\">",
"      Zupa��ska B, Lawkowicz W, G&oacute;rska B, et al. Autoimmune haemolytic anaemia in children. Br J Haematol 1976; 34:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/7\">",
"      Wolach B, Heddle N, Barr RD, et al. Transient Donath-Landsteiner haemolytic anaemia. Br J Haematol 1981; 48:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/8\">",
"      Heisel MA, Ortega JA. Factors influencing prognosis in childhood autoimmune hemolytic anemia. Am J Pediatr Hematol Oncol 1983; 5:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/9\">",
"      Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica 2011; 96:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/10\">",
"      Vaglio S, Arista MC, Perrone MP, et al. Autoimmune hemolytic anemia in childhood: serologic features in 100 cases. Transfusion 2007; 47:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/11\">",
"      Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest 1972; 51:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/12\">",
"      Atkinson JP, Frank MM. Complement-independent clearance of IgG-sensitized erythrocytes: inhibition by cortisone. Blood 1974; 44:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/13\">",
"      Atkinson JP, Frank MM. Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest 1974; 54:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/14\">",
"      Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest 1976; 58:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/15\">",
"      Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood 1987; 69:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/16\">",
"      Reusser P, Osterwalder B, Burri H, Speck B. Autoimmune hemolytic anemia associated with IgA--diagnostic and therapeutic aspects in a case with long-term follow-up. Acta Haematol 1987; 77:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/17\">",
"      Freedman J, Wright J, Lim FC, Garvey MB. Hemolytic warm IgM autoagglutinins in autoimmune hemolytic anemia. Transfusion 1987; 27:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/18\">",
"      Javid J. Human serum haptoglobins: a brief review. Semin Hematol 1967; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/19\">",
"      Bell CA, Zwicker H, Sacks HJ. Autoimmune hemolytic anemia: routine serologic evaluation in a general hospital population. Am J Clin Pathol 1973; 60:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/20\">",
"      Engelfriet CP, Overbeeke MA, von dem Borne AE. Autoimmune hemolytic anemia. Semin Hematol 1992; 29:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/21\">",
"      Nordhagen R, Stensvold K, Winsnes A, et al. Paroxysmal cold haemoglobinuria. The most frequent acute autoimmune haemolytic anaemia in children? Acta Paediatr Scand 1984; 73:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/22\">",
"      Bell CA, Zwicker H, Rosenbaum DL. Paroxysmal cold hemoglobinuria (P.C.H.) following mycoplasma infection: anti-I specificity of the biphasic hemolysin. Transfusion 1973; 13:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/23\">",
"      Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed) 1981; 282:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/24\">",
"      Nydegger UE, Kazatchkine MD, Miescher PA. Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin Hematol 1991; 28:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/25\">",
"      LEVINE P, CELANO MJ, FALKOWSKI F. THE SPECIFICITY OF THE ANTIBODY IN PAROXYSMAL COLD HEMOGLOBINURIA (P.C.H.). Transfusion 1963; 3:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/26\">",
"      Rosse WF. Fixation of the first component of complement (C'la) by human antibodies. J Clin Invest 1969; 47:2430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/27\">",
"      Fong KY, Loizou S, Boey ML, Walport MJ. Anticardiolipin antibodies, haemolytic anaemia and thrombocytopenia in systemic lupus erythematosus. Br J Rheumatol 1992; 31:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/28\">",
"      Boling EP, Wen J, Reveille JD, et al. Primary Sjogren's syndrome and autoimmune hemolytic anemia in sisters. A family study. Am J Med 1983; 74:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/29\">",
"      Blanchette VS, Hallett JJ, Hemphill JM, et al. Abnormalities of the peripheral blood as a presenting feature of immunodeficiency. Am J Hematol 1978; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/30\">",
"      Pui CH, Wilimas J, Wang W. Evans syndrome in childhood. J Pediatr 1980; 97:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/31\">",
"      Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 2006; 132:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/32\">",
"      Wang W, Herrod H, Pui CH, et al. Immunoregulatory abnormalities in Evans syndrome. Am J Hematol 1983; 15:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/33\">",
"      Pegels JG, Helmerhorst FM, van Leeuwen EF, et al. The Evans syndrome: characterization of the responsible autoantibodies. Br J Haematol 1982; 51:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/34\">",
"      Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005; 105:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/35\">",
"      Sthoeger ZM, Sthoeger D, Shtalrid M, et al. Mechanism of autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 1993; 43:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/36\">",
"      Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 1982; 72:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/37\">",
"      Chu JY. Autoimmune hemolytic anemia in childhood Hodgkin's disease. Am J Pediatr Hematol Oncol 1982; 4:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/38\">",
"      Sokol RJ, Hewitt S, Booker DJ. Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes. J Clin Pathol 1989; 42:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/39\">",
"      O'Brien TA, Eastlund T, Peters C, et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol 2004; 127:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/40\">",
"      G&ouml;ttsche B, Salama A, Mueller-Eckhardt C. Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases. Vox Sang 1990; 58:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/41\">",
"      Murray HW, Masur H, Senterfit LB, Roberts RB. The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med 1975; 58:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/42\">",
"      Rosenfield RE, Schmidt PJ, Calvo RC, McGinniss MH. Anti-i, a frequent cold agglutinin in infectious mononucleosis. Vox Sang 1965; 10:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/43\">",
"      Rollof J, Eklund PO. Infectious mononucleosis complicated by severe immune hemolysis. Eur J Haematol 1989; 43:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/44\">",
"      Boccardi V, D'Annibali S, Di Natale G, et al. Mycoplasma pneumoniae infection complicated by paroxysmal cold hemoglobinuria with anti-P specificity of biphasic hemolysin. Blut 1977; 34:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/45\">",
"      K&ouml;nig AL, Schabel A, Sugg U, et al. Autoimmune hemolytic anemia caused by IgG lambda-monotypic cold agglutinins of anti-Pr specificity after rubella infection. Transfusion 2001; 41:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/46\">",
"      Terada K, Tanaka H, Mori R, et al. Hemolytic anemia associated with cold agglutinin during chickenpox and a review of the literature. J Pediatr Hematol Oncol 1998; 20:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/47\">",
"      Rickard KA, Robinson RJ, Worlledge SM. Acute acquired haemolytic anaemia associated with polyagglutination. Arch Dis Child 1969; 44:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/48\">",
"      Petz LD. Drug-induced immune haemolytic anaemia. Clin Haematol 1980; 9:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/49\">",
"      Salama A, Mueller-Eckhardt C. On the mechanisms of sensitization and attachment of antibodies to RBC in drug-induced immune hemolytic anemia. Blood 1987; 69:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/50\">",
"      Wallhermfechtel MA, Pohl BA, Chaplin H. Alloimmunization in patients with warm autoantibodies. A retrospective study employing three donor alloabsorptions to aid in antibody detection. Transfusion 1984; 24:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/51\">",
"      Salama A, Bergh&ouml;fer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992; 340:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/52\">",
"      Fries LF, Brickman CM, Frank MM. Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy. J Immunol 1983; 131:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/53\">",
"      Collins PW, Newland AC. Treatment modalities of autoimmune blood disorders. Semin Hematol 1992; 29:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/54\">",
"      Meytes D, Adler M, Viraq I, et al. High-dose methylprednisolone in acute immune cold hemolysis. N Engl J Med 1985; 312:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/55\">",
"      Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/56\">",
"      Bussel JB, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986; 51:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/57\">",
"      Bernstein ML, Schneider BK, Naiman JL. Plasma exchange in refractory acute autoimmune hemolytic anemia. J Pediatr 1981; 98:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/58\">",
"      Imgrueth M, Wagner HP, Pipczynski-Suter K, et al. Plasma exchange: an important part of the therapeutic procedure in a small child with autoimmune hemolytic anemia. Acta Paediatr Scand 1986; 75:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/59\">",
"      Silberstein LE, Berkman EM. Plasma exchange in autoimmune hemolytic anemia (AIHA). J Clin Apher 1983; 1:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/60\">",
"      Current status of therapeutic plasmapheresis and related techniques. Report of the AMA panel on therapeutic plasmapheresis. Council on Scientific Affairs. JAMA 1985; 253:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/61\">",
"      Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/62\">",
"      Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101:3857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/63\">",
"      Kim JJ, Thrasher AJ, Jones AM, et al. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol 2007; 138:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/64\">",
"      Bader-Meunier B, Aladjidi N, Bellmann F, et al. Rituximab therapy for childhood Evans syndrome. Haematologica 2007; 92:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/65\">",
"      Giulino LB, Bussel JB, Neufeld EJ, Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr 2007; 150:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/66\">",
"      CHERTKOW G, DACIE JV. Results of splenectomy in auto-immune haemolytic anaemia. Br J Haematol 1956; 2:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/67\">",
"      Parker AC, MacPherson AI, Richmond J. Value of radiochromium investigation in autoimmune haemolytic anaemia. Br Med J 1977; 1:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/68\">",
"      Coon WW. Splenectomy in the treatment of hemolytic anemia. Arch Surg 1985; 120:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/69\">",
"      Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993; 83:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/70\">",
"      Agnello V, Pariser K, Gell J, et al. Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement. J Rheumatol 1983; 10:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/71\">",
"      Ahn YS, Harrington WJ, Byrnes JJ, et al. Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets. JAMA 1983; 249:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/59/18362/abstract/72\">",
"      Medellin PL, Patten E, Weiss GB. Vinblastine for autoimmune hemolytic anemia. Ann Intern Med 1982; 96:123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5934 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18362=[""].join("\n");
var outline_f17_59_18362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H46\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secondary AIHA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY OF RED CELL DESTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Warm-reactive AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cold-reactive AIHA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patient history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Reticulocyte count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Direct antiglobulin test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IMMUNOHEMATOLOGIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antigenic reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Spherocytes and other red cell alterations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dark urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Jaundice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SECONDARY AUTOIMMUNE HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Evans syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Warming",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Exchange transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H957606\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Post-splenectomy care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Danazol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/5934\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5934|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/9/38046\" title=\"figure 1\">",
"      Immune clearance of red cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5934|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/1/27670\" title=\"picture 1\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/10/15527\" title=\"picture 2\">",
"      Cold agglutinin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/10/32935\" title=\"picture 3\">",
"      Warm reactive AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/21/9552\" title=\"picture 4\">",
"      Nucleated RBC in AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/9/31895\" title=\"picture 5\">",
"      Polychromatophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/45/39638\" title=\"picture 6\">",
"      Howell-Jolly bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/36/43589\" title=\"picture 7\">",
"      Erythroid hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/7/40050\" title=\"picture 8\">",
"      Erythroid precursors marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 9\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5934|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/26/16811\" title=\"table 1\">",
"      Classification of AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/53/13148\" title=\"table 2\">",
"      Pathophysiology and therapy of AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/16/15627\" title=\"table 3\">",
"      Factors in immune hemolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27303?source=related_link\">",
"      Hematologic problems in children and adolescents with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12597?source=related_link\">",
"      Indications for therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=related_link\">",
"      The incompatible crossmatch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_59_18363="Sulfonamide agents";
var content_f17_59_18363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Groups of sulfonamide medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antimicrobials",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulfamethoxazole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulfamerazine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulfamethizole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulfamoxole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulfamethazine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulfoxazole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulfapyridine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Non-antimicrobials (diuretics, triptans, oral hyopglycemics, antiinflammatories)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Furosemide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bumetanide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hydrochlorothiazide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acetazolamide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diazoxide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sumatriptan",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glyburide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Celecoxib",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulfasalazine",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18363=[""].join("\n");
var outline_f17_59_18363=null;
var title_f17_59_18364="Disadv main Rx prost CA";
var content_f17_59_18364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The disadvantages of the main treatment options for early prostate cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        External beam radiation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant risk of impotence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Best outcomes require 3-D conformal treatments with doses above 72 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low risk of later rectal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knowledge of possible metastasis to lymph nodes is not available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Up to half of patients have some temporary bladder or bowel symptoms during treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Brachytherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant risk of impotence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Successful cancer control is operator dependent, to some extent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low risk of later rectal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knowledge of possible metastasis to lymph nodes is not available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment not appropriate for tumor outside the prostate capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Up to half of patients have some temporary bladder or bowel symptoms with treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Radical prostatectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant risk of impotence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of operative morbidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The risk of complications is operator dependent, to some extent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low risk of long-term incontinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Active observation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor may progress beyond the possibility for cure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Later treatment may result in more side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Living with untreated cancer may cause anxiety",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vogelzang NJ, Scardino PT, Shipley WU, et al. Comprehensive textbook of genitourinary oncology, 3rd Edition. Lippincott Williams &amp; Wilkins 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18364=[""].join("\n");
var outline_f17_59_18364=null;
var title_f17_59_18365="Infection risk factors in lung transplant recipients";
var content_f17_59_18365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for infection in lung transplant recipients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recipient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Underlying pathology (eg, diabetes/hepatitis) or other pathological history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of specific immunity to CMV, HSV, VZV, EBV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonization of the recipient by bacteria or fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Latent infection due to TB, CMV, VZV, HSV, EBV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous therapy with antimicrobial agents, and glucocorticoids or other immunosuppressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical state of the recipient at the time of transplantation: Renal failure, malnutrition, obesity, mechanical ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonization of the graft by bacteria or fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preservation lesion, arterial ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Surgical factors:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Duration of procedure, surgical technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Surgical complications: Suture dehiscence, hemorrhage, arterial ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Repeat surgery required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postoperative instrumentation: Duration of mechanical ventilation, intravascular catheters, urethral catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung allograft is continuously exposed to the external environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Denervation of allograft:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diminished cough reflex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abnormal mucociliary clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reactive hyperresponsiveness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interrupted lymphatic drainage (especially during first weeks)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Anastomosis site:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        May enhance colonization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Airway dehiscence and mediastinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchial stenosis and postobstructive infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Donor lung may transmit infections:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        From prolonged mechanical ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        From latent infections (TB, CMV, VZV, HSV, EBV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        From previous bacterial or fungal colonization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Native lung after single-lung transplantation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Occult pretransplant infection (TB, Aspergillus,",
"        <em>",
"         Pneumocystis jirovecii",
"        </em>",
"        , etc., especially with immunosuppression before transplantation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinus infection in cystic fibrosis and ciliary dysfunction syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bronchiolitis obliterans:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Enhanced immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Impaired clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bronchiectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunosuppressive agents: Cyclosporine, azathioprine, glucocorticoids, antilymphocyte antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunomodulating viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Graft rejection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CMV: cytomegalovirus; HSV: herpes simplex virus; VZV: varicella zoster virus; EBV: Epstein-Barr virus; TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Gavalda J, Roman A, Pahissa A, et al. Risks and epidemiology of infections after lung or heart-lung transplantation. In: Transplant Infections, 3rd ed, Bowden RA, Ljungman P, Snydman DR (Eds), Lippincott Williams &amp; Wilkins, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18365=[""].join("\n");
var outline_f17_59_18365=null;
var title_f17_59_18366="Diagram of laser components";
var content_f17_59_18366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Diagram of laser components",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18366=[""].join("\n");
var outline_f17_59_18366=null;
var title_f17_59_18367="CHH management";
var content_f17_59_18367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Suggested paradigm for initial and long-term management of individuals with cartilage-hair hypoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 401px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Our data suggest that many individuals with CHH can safely receive live vaccines, with the exception of the live rotavirus vaccine during the first year of life. Live vaccines should be avoided in CHH patients who clearly have SCID.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_59_18367=[""].join("\n");
var outline_f17_59_18367=null;
